

**Die Hyperbare Sauerstofftherapie (HBO)
im Therapiekonzept von Bestrahlungsfolgen**

**Osteoradionekrose (ORN)
Praevention von ORN
bei geplanter Zahnextraktion im bestrahlten Gebiet
vor Implantation im bestrahlten Gebiet**

in den Druckkammerzentren

des VDD e.V.



Verband Deutscher
Druckkammerzentren

Zusammenstellung von Informationen


für Ärzte

**Autor: Dr. med. Christian Heiden
Verband Deutscher Druckkammerzentren e.V. (VDD)
Cuno-Niggel-Str. 3, 83278 Traunstein
Tel. +49-861-12 589 Fax: +49-861-12 889
E-Mail: geschaeftsstelle@vdd-hbo.de
www.vdd-hbo.de**

Stand: 121114

1. Pathomechanismus der ORN

Die radiogene Schädigung von Normalgewebe führt zu einem breiten Spektrum früher und später Gewebsreaktionen und damit verbundenen klinischen Symptomen. Die Latenzzeit bis zum Auftreten einer Gewebsreaktion wird im Wesentlichen durch Zellzykluszeiten der bestrahlten Gewebe bestimmt. Veränderungen, die mehr als 90 Tage nach Beginn der Radiotherapie auftreten, gelten im Allgemeinen als irreversibel. Als zugrundeliegender Pathomechanismus „später Gewebsreaktionen“ werden Schädigungen von Parenchymzellen und Veränderungen der Endothelzellen in Kapillaren diskutiert [Hopewell 1974, Sminia 1995, Thiel 1989]. Histologisch wird eine obliterative Endarteriitis beschrieben.



Auf Grund der histopathologisch nachgewiesenen Hypovaskularität und Hypozellularität sowie der daraus resultierenden Hypoxie bezeichnet Marx [1983] derartig geschädigte Bereiche als „**3 H-Gewebe**“. Zellzykluszeiten normaler Endothelien von 47-230 Tagen unterstützen ferner die Annahme, daß Gewebs- und Organveränderungen, die nach großer Latenzzeit auftreten, durch Schädigungen der Endothelzellen verstärkt werden [Hobson und Denekamp 1984]. Veränderungen der Endothelien nach Bestrahlung sind somit ein wichtiger, wenn auch nicht der einzige, Pathomechanismus für das Entstehen später Gewebs- und Organveränderungen.

Gewebereaktion nach Radiatio

➡ Hypovaskularität + Hypozellularität + Hypoxie

Bis 6 Wochen: Proliferationshemmung, Entzündung

Bis 6 Monate: Reparationsvorgänge

Bis 1 Jahr: Progression des Kapillarverlustes

Bis 5 Jahre: Weitere Progression der "3 H"
ggf. Spontanulcera

Ab 5. Jahr Verlangsamte Progression

HBO-Traunstein

ZEITABLAUF DER BESTRAHLUNGSFOLGEN

- akute Phase - **bis 6. Monat**
Mucositis, ORN 1, stumme? Accumulation
- subakute Phase - **bis 2. Jahr**
Persistenz + Progredienz
- chronische Phase - **bis 5. Jahr**
Parenchymzerstörung, Infektoresistenz, Hypoperfusion
- Spätphase - **ab 6. Jahr**
Alterung, Zweit-TU

HBO-
Traunstein

Für den Strahlentherapeuten stellen Spätkomplikationen nach Strahlentherapie ein Problem dar, da nach Applikation einer bestimmten Energiedosis die Strahlenreaktion in einem Gewebe eigengesetzlich und bis zu einem bestimmten Endpunkt abläuft, ohne daß eine Beeinflussung von außen möglich ist. Strahlenschäden verlaufen lange nach Beendigung der Radiotherapie progredient, da geschädigte Zellen nicht replikationsfähig sind und die Replikation gesunder Zellen durch die unzureichende Vaskularisierung behindert wird. Der geringe Sauerstoffgradient führt zu Kollagenmangel und vermehrter Fibrosierung des bestrahlten Gewebes. Die Sauerstoffspannung im Zentrum eines ansonsten gesunden Bestrahlungsbereichs kann nur 5 bis 10 mmHg betragen (normal = 50 –60, Problemwunden haben < 20mmHg) [Marx und Johnson 1988].

Strahlenwirkung auf Knochengewebe

Knochen adsorbiert aufgrund seiner 1,8fach höheren Dichte eine größere Strahlendosis als Weichteilgewebe. Die Strahlung verändert die vaskulären und zellulären Knochenkomponenten gleichermaßen. Hohe Strahlendosen zerstören die Blutgefäße zwi-

schen Periost und Knochenoberfläche mit konsekutiver Osteonekrose. [Marx et al. 1987, Mounsey et al. 1993, van Merkesteyn et al. 1995]. Auch stören sie die Balance zwischen osteoklastischem Knochenabbau und osteoblastischem Aufbau zu Ungunsten der Osteoblasten mit der Folge einer Osteoporose, die üblicherweise

4 Monate bis mehrere Jahre nach der Bestrahlung manifest wird. Besonders häufig werden Nekrosen in den folgenden Arealen beobachtet :

- Mandibula, insbesondere nach Radiotherapie von Weichteiltumoren im Kopf-Hals-Bereich. Die Mandibula adsorbiert aufgrund ihrer höheren Dichte mehr Strahlung als die Maxilla und tendiert wegen der schlechteren Vaskularisierung leichter zur Nekrotisierung.
- Rippen, Klavikel und Sternum nach thorakaler Radiotherapie,
- Schädel nach Bestrahlung eines Hirntumors oder eines Weichteiltumors der Kopfhaut,
- Wirbelsäule infolge Bestrahlung von Rückenmarkstumoren,
- Becken und Femurkopf nach Bestrahlung von Becken-tumoren

Wegen der ohnehin im Vergleich zu sonstigen Knochen ungünstigen (spärlichen) Gefäßarchitektur gilt die Mandibula als besonders anfällig. Zahnextraktionen im Strahlentherapiegebiet induzieren Wunden, die in einer „3H-Umgebung“ in einem relevanten Prozentsatz von bis zu 50% der Fälle (sehr unterschiedliche Zahlen in der Literatur !) eine Knochennekrose induzieren.

Die bestrahlte Haut

kann ihre physiologischen Aufgaben nicht mehr erfüllen. Die Oberflächenstruktur ist aufgelockert und die Hautdrüsenfunktion derart reduziert, daß pathogene Keime leicht in subkutane Gewebe vordringen können, Zugang zu nekrotischen Knochen haben und dort gute Wachstumsbedingungen finden.

Subkutanes Fettgewebe,

daß normalerweise ohnehin nur gering perfundiert wird, bietet optimale Lebensbedingungen für Keime unterschiedlicher Aggressivität. Beobachtungen zufolge kommt es zu abszedierten Veränderungen. Die betroffene Region wird nekrotisch und wird abgestoßen. Derartige Prozesse werden selbst noch 30 Jahre und länger nach einer erfolgten Strahlenbehandlung beobachtet [Feldmeier et al. 1996]. Eine weiträumige chirurgische Intervention dieser Form von Weichteilradionekrose mit plastischer Dekung führt zu zusätzlicher Hospitalisierung ohne Erfolgsgarantie.

Schleimhäute

im Mundbereich sind infolge einer regelmäßig anzutreffenden **Xerostomie** immer trocken und stellen daher Eintrittspforten für Keime dar. Die obligatorisch unterschiedlich intensiv auftretende Strahlensialose führt für den Patienten zu sehr lästigen Trockenheitsbeschwerden, die bis zur völligen Austrocknung mit rissiger Schleimhaut führen können. Zähne müssen praktisch ständig von normalem Speichel benetzt sein um gesund zu bleiben. Deshalb führt eine ausgeprägte Xerostomie regelmäßig auch zur kariösen Zerstörung der Zähne. Auch bei Zahnsanierung vor Bestrahlungsbeginn müssen daher im weiteren Verlauf häufig noch Zähne gezogen werden.

Klinische Anwendung der HBO - Osteoradionekrose


Begünstigung von Strahlenfolgen

- Strahlendosis (pro Zeit)
- Absorptionsgrad von Strahlen
- Schutzfunktion von:
Haut
Subcutis,
Schleimhaut

HBO-Traunstein

Bei **frühen radiogen Nebenwirkungen** wird regelmäßig eine ödematöse Schwellung der Normalgewebszellen im Zielvolumen beobachtet. Die Symptomatik hängt davon ab, welche Normalgewebe betroffen sind. Die klinischen Verläufe sind unterschiedlich schwer. Oft muß die Strahlenbehandlung wegen Nebenwirkungen unterbrochen werden, so daß eine Repopulierung der Tumoren das Ziel der lokalen Tumorkontrolle ungünstig beeinflussen kann.

2. Therapeutischer Nutzen der HBO bei Bestrahlungsfolgen



Konventionelle Therapiemodalitäten versagen bei der Strahlennekrose, da eine ausreichende Versorgung der devaskularisierten Gewebe mit Nährstoffen, Medikamenten und Sauerstoff nicht möglich ist. Die sehr schmerzhaften Strahlenulzera erfordern den Einsatz hochpotenter Analgetika, die zur Suchtentwicklung führen können. Rekonstruk-

tive Eingriffe zeichnen sich durch hohe Mißerfolgsraten und Wundheilungsstörungen aus.

Die enttäuschenden Ergebnisse konventioneller Maßnahmen führten zum versuchsweisen Einsatz der HBO bei Radionekrosen, da sie den Gewebe-pO₂ auf normale Werte anhebt und die Kollagenbildung im Wundrandgebiet stimuliert, die ihrerseits die Mikrovaskularisierung anregt. Die verbesserte Durchblutung fördert die Reepithelialisierung kleiner Ulzera und verbessert das Angehen von Transplantaten und

gestielten Lappen. Gewebesauerstoffstudien ergaben nach acht HBO-Behandlungen eine meßbare Angiogeneese, die nach 20 Anwendungen 80% bis 85% der Gefäßversorgung unbestrahlter Gewebe erreichte und auch nach Therapieabbruch auf diesem Niveau verharrte [Marx et al. 1985].

Der HBO-Behandlung von Radionekrosen liegen die gleichen Überlegungen zugrunde wie bei Wundheilungsstörungen. Gelegentlich sind Knochenimplantate zur Rekonstruktion bei Radionekrose unumgänglich. Larsen et al. [1993] bestrahlten Rattentibiae in tumorzerstörender Dosierung und führten anschließend beidseitig Knochentransplantationen durch. Im Vergleich zur kontralateralen Kontrollseite steigerte die adjuvante HBO den Grad der histologischen Implantatintegration.

Zahlreiche experimentelle Untersuchungen und klinische Studien belegen, daß Spät-komplikationen nach Strahlentherapie mit hyperbarer Oxygenierung wirksam behandelt werden können.

Durch frühzeitigen Einsatz von HBO werden die Erfolgsaussichten der plastischen Deckung von **Defekten** erheblich verbessert. Möglicherweise kann bei kleineren Defekten sogar auf eine Operation verzichtet werden. Marx et al. [1990] sehen in derartigen Fällen etwa 30-40 prä-operative HBO-Einheiten nach dem Problemwundenschema vor. Postoperativ sind weitere 10 Therapieeinheiten vorgesehen, um die Einheilung von Transplantationsgewebe zu fördern.

Klinische Anwendung der HBO im Mund- Kieferbereich

- Mucositis
- Osteoradionekrose (Mandibula) primär, sekundär (Zahnextraktion, OP)
- Xerostomie
- gefährdete Transplantate
- Sicherung osteointegrierter Implantate
- Mundbodengrän (Fournier)
- Strahlensensitivierung bei Rezidivtumoren
- Sonstige Strahlennebenwirkungen

HBO-Traunstein

Am besten wurde in der Fachliteratur die Behandlung von **Osteoradionekrosen** des Mund-Kiefer-Bereiches mit HBO dokumentiert [c.f. Hartmann et al. 1996]. Auch die prophylaktische HBO-Behandlung bei **Zahnextractionen** im bestrahlten Gebiet führte im Rahmen einer prospektiv randomisierten Studie zur hochsignifikanten Reduktion ($p=0.0005$) der Inzidenz von Osteoradionekrosen von 29.9% auf 5.4% [Marx et al. 1985]. In den Behandlungsarmen wurde die alleinige Prophylaxe mit HBO der antibiotischen Abdeckung gegenübergestellt. Ashamalla et al. [1996a] beobachteten nach 20

HBO-Therapien eine beginnende Neovaskularisation im bestrahlten Gebiet. Bei ihm hat sich zusätzlich die postoperative HBO-Behandlung mit 10 weiteren Einheiten bewährt [Ashamalla et al. 1996a].

Die mandibuläre Osteoradionekrose stellt die häufigste Spätkomplikation der Radiotherapie von Tumoren im Kopf-Hals-Bereich und insbesondere der Mundhöhle dar. In der Publikation von Hart und Strauss [1986] entwickelten 235 von 378 Patienten (62,2%) diese Komplikation, die durch die ausschließliche Blutversorgung über die Knochenmatrix und die Nähe des Tumors zur Mandibula begünstigt wird.

Radiologisch finden sich bei der Mandibularnekrose in der Regel zahlreiche Läsionen einschließlich Osteolysen und pathologischen Frakturen. Gelegentlich sind die Röntgenaufnahmen aber auch unauffällig, oder die Abweichungen korrelieren nicht mit der Klinik. Entgegen der früheren Annahme, eine Infektion sei immer an der Pathogenese der Osteoradionekrose beteiligt, geht man heute vorwiegend von einem aseptischen Prozeß aus.

Von den 206 Patienten, die Hart und Strauss [1986] mittels ergänzender HBO behandelten, zeigten 72% ausgezeichnete Ergebnisse, 10% gute und 15% mäßige Resultate. Bei den restlichen 3% blieb die HBO wirkungslos. [Guernsey und Clark 1981; Patel et al. 1989; Fattone und Strauss 1987].

<p style="text-align: center;">Klinische Anwendung der HBO</p> <h3 style="text-align: center;">Osteoradionekrose - Stadium 1</h3> <ul style="list-style-type: none">• Definition: ohne Fisteln, Frakturen, Knochenresorption• Therapie: 30 Sitzungen HBO TS-240/90 Re-Evaluation ev. weitere 10 <p>Marx(83) HBO-Traunstein</p>
<p style="text-align: center;">Klinische Anwendung der HBO</p> <h3 style="text-align: center;">Osteoradionekrose - Stadium 2</h3> <ul style="list-style-type: none">• Definition: Nonresponder von I nur kortikale Knochenbeteiligung ohne Knochenresorption ohne Indikation zur Unterkieferresektion• Therapie: Nekrosenabtragung / Debridement + HBO TS-240/90 30 Sitzungen HBO TS-240/90 Re-Evaluation ev weitere 10 <p>Marx(83) HBO-Traunstein</p>

Klinische Anwendung der HBO

Osteoradionekrose - Stadium 3

- **Definition:**
Indikation zur Unterkieferresektion
- **Therapie:**
erst 20x HBO TS 240/90 dann
radikale Resektion dann 10xHBO dann
Rekonstruktion dann weitere 10x HBO

Marx(83)

HBO-Traunstein

Klinische Anwendung der HBO

Osteoradionekrose

- 235 von 378 Patienten (62,2%) erlitten ORN
- HBO N=206
72% ausgezeichnete
10% gute
15% mäßige
3% ohne Erfolg

Hart und Strauss [1986]

HBO-Traunstein

Klinische Anwendung der HBO

Unterkieferrekonstruktion

Erfolgskriterien

- Kontinuität
- alveoläre Knochenhöhe
- Knochenstärke
- Persistenz des Transplantates
- Weichteildefekte beseitigt
- Gesichtsform

HBO-Traunstein

Klinische Anwendung der HBO

Unterkieferrekonstruktion

Kriterien)	N	Komplikationen	Erfolg (6
ohne - HBO	52	11 (22%)	34 (65%)
HBO	52	5 (9%)	48 (92%)

Marx 1965

HBO-Traunstein

Klinische Anwendung der HBO

Unterkieferrekonstruktion

268 Patienten in 8 Jahren

Rückbildung der Läsionen bei

38 Patienten der Stufe I (14%)

48 Patienten der Stufe II (18%)

182 Patienten (68%) der Stufe III

Marx

HBO-Traunstein

Nach einer Auswertung der Literatur und Durchsicht seiner eigenen Erfahrungen folgte Davis [1981]:

Die physiologischen Verhältnisse und die experimentell gewonnenen Daten zur Wirkung des hyperbaren Sauerstoffs bei Radionekrosen werden durch fast identische Ergebnisse in zahlreichen Zentren bestätigt und machen sowohl die Weichteil- als auch die Osteoradionekrose zu zwingenden Indikationen für eine adjuvante HBO.

Klinische Anwendung der HBO

ORN nach Zahnextraktion

- bei HBO adjuvant 83.0% signifikant besser
- N = 41

Mounsey et al. [1993]

HBO-Traunstein

Klinische Anwendung der HBO

ORN nach Zahnextraktion

- bei Penizillintherapie 29.9%
- bei HBO adjuvant 5.4%

Marx et al. 1985

HBO-Traunstein

Therapieschema:

In synoptischer Betrachtung bekannter Daten in der Therapie sämtlicher radiogenen Nebenwirkungen ergibt sich ein Spielraum zwischen 20 und 60 HBO-Therapieeinheiten. Nach Feldmeier et al. [1996] sind weniger als 20 Behandlungen nicht suffizient. Ab 30 HBO-Einheiten nimmt die Erfolgsrate deutlich zu. Erfahrungen zeigen, daß in den meisten Fällen zwischen 25 und 40 Behandlungen notwendig sind. Evtl. muß postopativ die Therapie fortgesetzt werden, wenn bei plastischer Deckung das Transplantat gefährdet ist. In der Regel wird die Gesamtzahl von 60 HBO-Einheiten nicht überschritten werden müssen

Empfohlen wird das sog. Problemwundenschema mit 3x30 Minuten Sauerstoffatmung bei 140 kPa Überdruck [Hartmann et al. 1996]. Die Gesamtdauer jeder Sitzung mit „Luft-Pausen“ beträgt 135 Minuten.

Osteointegrierte Implantate

Für die Osteointegration von Implantaten gilt grundsätzlich, daß der präoperative Zustand des Patienten durch ein Versagen der Methode nicht verschlimmert werden darf.

In Ermangelung kausaler Behandlungsmethoden war die Vorbestrahlung daher ein Ausschlußkriterium (Taylor).

Implantate – meist aus Titan – werden im Kopf-Halsbereich vor allem zur Fixierung von Zahnersatz oder von Epithesen zur Gesichtsrekonstruktion eingesetzt.

Klinische Anwendung der HBO

osteointegrierte Implantate

im bestrahlten Gebiet

- 50 Gy gilt als Kontraindikation für Implantation ohne Vorbereitung
- Implantverluste bestrahltes Gebiet ohne HBO in 14 Jahren 53,7%
- Implantverluste unbestrahltes Gebiet ohne HBO in 14 Jahren 13,5%

Granström 1994 HBO-Traunstein

Werden in einem vorbestrahlten Knochen Implantate eingesetzt, beträgt die Verlustrate in einem Zeitraum von 10 Jahren bis zu 50%. Durch prophylaktische HBO wird die Verankerung von Zahnersatz, Obturatoren, Alloplastiken und Epithesen mittels osteointegrierter Fixateure auch für Patienten nach Radiatio zu einer sicheren Behandlungsmethode, denn HBO senkt die Verlustrate osteointegrierter Implantate und vermindert postoperative Komplikationen (Marx). Durch prophylaktische HBO wird der Einfluß der Vorbestrahlung auf die Verlustrate osteointegrierter Implantate praktisch aufgehoben. [Granström 1994].).

Die perioperative HBO fördert die Knochenbildung an der Grenzfläche des Implantates zum Knochen (Granström 1994) und verbessert die Mikrozirkulation der entsprechenden Region. Das führt zu einer verbesserten Festigkeit von Implantaten (Granström 1996) und gleichzeitig zu einem verbesserten Zustand der Weichteildeckung. Somit wird durch adjunktive Anwendung hyperbaren Sauerstoffs sowohl die Haltbarkeit von Befestigungen gesteigert, als auch möglichen Wundheilungsstörungen und Komplikationen wie Osteoradionekrose entgegen gewirkt (Granström 1993).

Klinische Anwendung der HBO

osteointegrierte Implantate

im bestrahlten Gebiet

- HBO fördert:
- Knochenbildung an der Grenzfläche Knochen / Implantat
- Mikrozirkulation durch Angiogenese
- Verbesserung der Weichteildeckung
- dadurch die Festigkeit der Implantate

Granström 1996 HBO-Traunstein

Klinische Anwendung der HBO
osteointegrierte Implantate
im bestrahlten Gebiet

- HBO verhindert:
- Wundheilungsstörungen im bestrahlten Gebiet
- Osteoradionekrose nach Zahnextraktion
- Osteoradionekrose nach OP am Knochen wie Implantat

Granström 1993

HBO-Traunstein

Klinische Anwendung der HBO
osteointegrierte Implantate
im bestrahlten Gebiet

- Nach HBO praktisch keine Implantatverluste in den ersten 6 Jahren
- nach 14 Jahren in der HBO Gruppe 8,1% Implantatverluste im bestrahlten Gebiet
- gleichwertige Ergebnisse wie bei unbestrahlten Patienten

Granström 1998

HBO-Traunstein

Entsprechend ergaben die Nachuntersuchungen von Ganström et al., daß Implantatverluste in der HBO-Gruppe während der ersten 6 Jahre nicht beobachtet wurden und die Implantat-Verlustrate während des gesamten Beobachtungszeitraums von inzwischen 14 Jahren sogar konstant niedriger als in der Kontrollgruppe ohne Radiatio war.

Klinische Anwendung der HBO

osteointegrierte Implantate

im bestrahlten Gebiet

	Ohne HBO	Mit HBO
Extraoral	58%-65% (Parel)	97% (Granström)
Maxilla	55%-86% (Eckert, Lorant Granström)	91%-100% (Samtt, Nimi, Ueda, Granstr.)
Mandibula	67%-99% (Eckert*, Granström)	100% (Barber, Taylor, Ueda, Granström)
Transplantat	74%-77% (Buchbinder, Martin)	100% (Barer)

Larsen 1997

HBO-Traunstein

Klinische Anwendung der HBO

osteointegrierte Implantate

im bestrahlten Gebiet

	Mit HBO Nimi et al.	Ohne HBO US-Multiz.	Ohne HBO schwed. Zahln
Erfolg 1. Jahr	91,7% (11/12)	70,6 (36/51)	78,9% (45/57)
Erfolg 2. Jahr	83,3% (10/12)		

Nimi et al. 1993

HBO-Traunstein

HBO bei Strahlenfolgen

Behandlungsgrundsatz

Der präoperative Zustand des Patienten darf durch ein Versagen von erforderlichen Behandlungsmaßnahmen nicht verschlechtert werden

HBO-Traunstein

Bei **frühen radiogen Nebenwirkungen** stehen zwar derzeit keine geeigneten Daten zum therapeutischen Nutzen von HBO zur Verfügung. Allerdings bietet die antiödematöse Wirkung der HBO bei akuten Nebenwirkungen die Möglichkeit einer schnellen und effektiven Interventionsmöglichkeit. Bei Patienten, bei denen bei Therapieende sehr starke Nebenwirkungen bestehen, ist oft zu beobachten, daß diese Reaktionen nicht abheilen, sondern direkt in chronische Bestrahlungsfolgen übergehen. Der frühe Einsatz von HBO kann zu einer Verbesserung der Lebensqualität beitragen, während gleichzeitig volkswirtschaftlicher Nutzen aus der Verkürzung der Krankheitsdauer gezogen wird.

Klinische Anwendung der HBO

Mucositis + nekrot. Infektionen

- Förderung der Oxygenierung im Schwellungsbereich
- Oedemreduktion
- Aktivierung der Infektabwehr
- Beschleunigung der Heilung durch Aktivierung der Zellsysteme

HBO-Traunstein

Klinische Anwendung der HBO

radiogene Xerostomie

- lang anhaltende Besserung - auch der Ruhesalivation (in 3 kleineren Studien)
- Sekundärgewinn bei Kariesreduktion, Infektionsminderung, Schleimhautschutz und Lebensqualität,
- relativiert Kosten

HBO-Traunstein

radiogene Xerostomie

Ergebnisse

	unstimuliert vor HBO	unstimuliert nach HBO	stimuliert vor HBO	stimuliert nach HBO
1	0,10	0,77	0,26	1,06
2	0,13	0,83	0,23	1,00
3	0,17	0,26	0,26	0,37
4	0,23	1,27	0,33	1,30
5	0,26	0,26	0,33	1,52
6	0,20	1,50	0,30	1,67
KONTROLLE N=12			1,3	1,57
ORN N=8			0,33	0,61

Fontanesi et al. 1991

HBO-Traunstein

radiogene Xerostomie

Studien

- Schmutz 1996
- Fontanesi et al. 1991
- Granström et al. 1992
- Roveda et al 1993

HBO-Traunstein

3. Risiken

Bei Tumorpatienten werden regelmäßig die Grundsätze von elektiven Therapien berührt. Beispielsweise ist eine radiogene **Lungenfibrose** nach Bestrahlung wegen

Brochialkarzinom nur eine relative Kontraindikation wenn die HBO-Therapie einer Weichteilradionekrose notwendig ist. Die besondere Problematik der beschriebenen Situation besteht in der Gefahr von Lungenrupturen i.S. von Barotraumen mit Luftembolie. Größer ist jedoch die Gefahr, daß eine schlecht heilende Weichteilnekrose über eine Sepsis letal verläuft.

Die generelle Toxizität von HBO für **Lunge und ZNS** ist in der derzeit angewendeten Therapie (bis 1.5 bar, max. 2.5 h) von HBO relativ gering [Welslau und Almeling 1996]. Erst ab 60 konsekutiven Therapieeinheiten steigt das Risiko der irreversiblen Lungenschädigung.

**Wird
Tumorwachstum
durch
Tumoroxygenierung
gefördert?**

HBO-Traunstein

Ein weiterer Aspekt ist die Frage, ob Tumorwachstum und Metastasierung von HBO begünstigt werden. In dem derzeit allgemein akzeptierten Mechanismus für die Entstehung von Metastasen werden viele Schritte kaskadenförmig durchlaufen. Selbst wenn einzelne Schritte von HBO begünstigt werden, so ist die Transformation von Zellen zu Tumorzellen identischen histologischen Typs, die als Rezidiv oder Metastase aufzufassen wären, durch HBO unwahrscheinlich. [Wittekind und Tannapfel 1996].

HBO fördert Tumorwachstum ?

widerlegt in

- in vitro Studien
- tierexperimentellen Studien
- klinischen Studien

HBO-Traunstein

HBO fördert Tumorwachstum ?

widerlegt in

- in vitro Studien
Kains et al. 1999, Teicher et al 1988, Wheeler et al 1979

HBO-Traunstein

HBO fördert Tumorwachstum ?

widerlegt in

Kains et al. 1999, In Vitro Cell Dev Biol Amin 35(1999)
98

- an Prostata-CA Zellen
- DNA-Produktion Dosisabhängig (p O₂)
akkumuliert in G2/M Stadium

HBO-Traunstein

HBO fördert Tumorwachstum ?

widerlegt in

- tierexperimentellen Studien
Brizel et al. 1997, Sklizovic et al. 1993, Ehler et al. 1991, Headley et al 1991, Nemiroff 1988 + 1991, Mestrovic et al 1990, McMillan et al. 1989, Marx et al 1988, Milas 1983, Harmon et al 1983, Ihde et al 1975, Fujimura 1974,

HBO-Traunstein

HBO + Tumorwachstum tierexperimentelle Studien

Brizel et al. 1997 Radiatio kombiniert mit :

- HBO od. Carbogen od. Carbogen + Nicotinamid
- Verhältnis von praetherapeutischer Oxygenation und Wachstumsrate
- Ratten in 7 Gruppen: Placebo-Radiatio, Luft, HBO 3 ATA, Nicotinamid, Carbogen, HBO + Nicotinamid
Carbogen + Nicotinamid

HBO-Traunstein

Feldmeier et al. [1994] und Almeling et al. [1996] haben vorhandene Daten analysiert. Weder die Inzidenz von Metastasen noch die von Rezidiven kann von HBO erhöht werden, da es hierfür notwendig ist, daß Tumorzellen vom gleichen histologischen Typ entstehen. Viel naheliegender ist es, daß die HBO Einfluß auf die Wachstumskinetik von Zellen nimmt, die die entsprechend zu erwartenden Rezidive und Metastasen verursachen. In vitro Studien, tierexperimentelle Studien und klinische Erhebungen widerlegen diese Befürchtungen.

Bei ohnehin palliativen Maßnahmen haben die Patienten am Ende bei bilanzierter Betrachtung von der HBO profitiert, weil das ihnen verbliebene Leben bei guter Palliation ohne größere Defekte und Wundheilungsstörung erhalten wurde. Entsprechendes wird von eigenen Einzelbeobachtungen belegt.

4. Wirtschaftlichkeit

Eine Ermittlung der gesamten durch die Erkrankung verursachten Kosten ist in Deutschland aufgrund der Struktur unseres Sozialwesens nicht möglich, weil unterschiedliche Institutionen Teilkostenbereiche abdecken und die Zusammenführung von Daten nicht möglich ist (Krankenkassen, kassenärztliche Vereinigungen, Rentenversicherungsträger, Sozialfürsorge, Arbeitgeber etc.) Selbst die Kassen können ihre Daten von Medikamentenverbrauch, Hilfsmitteln und ambulanten mit stationären Behandlungskosten nicht zusammenführen. Aus diesem Grund ist die Forderung an die „Anbieter“ der HBO, die Wirtschaftlichkeit ihrer Maßnahmen nachzuweisen zwar verständlich, aber ungerechtfertigt, weil niemand die globale Wirtschaftlichkeit irgend einer Maßnahme im Gesundheitswesen belegen kann. Wohl aber kann man die wirtschaftlichen Vorteile anhand von Einzelbetrachtungen mit Vergleich von Teilkosten beurteilen. (Vergleich Aufenthaltsdauer, Berentung/Arbeitsfähigkeit u.Ä.).

In den USA wurden solche Wirtschaftlichkeitsnachweise erbracht – die verhältnisse im Sozialversicherungswesen sind jedoch so unterschiedlich, daß die Ergebnisse nicht ohne Weiteres auf andere Länder übertragen werden können.

Ashamalla et al. [1996b] gehen ausführlich auf die volkswirtschaftliche Bilanz ein. Die Kosten eines kombinierten Therapiekonzeptes aus HBO-Therapie und chirurgischem Vorgehen für ORN liegen bei etwa € 15.000, wenn alle therapeutischen Optionen ausgeschöpft werden. Demgegenüber sind extreme Fälle bekannt, die herkömmlichen Behandlungen (ohne HBO) unterzogen werden: Z.B. ist bei einem Patienten 30 Jahre nach ventraler Kobalt-Bestrahlung (10cmx10cm-Feld), 2 Gy ED TDM, 46 Fraktionen (92 Gy Ges. Dosis) spontan eine tiefe Bauchdeckenulceration entstanden. Eine plastische Deckung ist wegen Fehlen von vitalem Adaptationsgewebe unmöglich. Bisher wurde der Patient für mehr als 4 Monate hospitalisiert. Eine demissio ist nicht absehbar. Bisher wurden für den Patienten, dessen Behandlung absehbar zu optimieren wäre (Lebensqualität!) bei Zugrundelegung eines Tagessatzes von nur € 150,- pro Tag bereits € 18.000,- verbraucht.

In einem Fall mit Strahlenschaden am Bein wurde konsequent HBO eingesetzt. nach 40 Therapieeinheiten war die chirurgische Intervention möglich. Der stationäre Aufenthalt betrug 30 Tage. Die betroffene Extremität konnte erhalten werden. Die Patientin kann sich ohne fremde Hilfe selbst versorgen Die Kosten bezifferten sich auf weniger als € 12.500,-.

Literatur:

Almeling M., W. Welslau, C. Plafki, M. Lerch: Does hyperbaric oxygen (HBO) have a cancer promoting effect. *Strahlenther Onkol* 172; Suppl II (1996), 30-31.

Ang, K.K., R.E. Price, L.C. Stephens, G.L. Jlang, Y. Feng, T.E. Schultheiss, L.J. Peters: The tolerance of primate spinal cord to re-irradiation. *Int J Radiat Oncol Biol Phys* 25 (1993), 459-464.

Ashamalla, H.L., S.R. Thom, J.W. Goldwein: Hyperbaric oxygen therapy for the treatment of radiation-induced sequelae in children. *Cancer* 77 (1996a), 2407-2412.

Ashamalla, H.L., J.W. Ames, A. Uri, P. Winkler: Hyperbaric oxygen in the management of osteoradionecrosis. *Med Pediatric Oncol* 27 (1996b), 48-53.

Feldmeier, J.J., J.D. Lange, S.D. Cox, L.J. Chou, V. Ciaravino: Hyperbaric oxygen as prophylaxis or treatment for radiation myelitis. *Undersea Hyperb Med* 20 (1993), 249-255.

Feldmeier, J.J., R.D. Heimbach, D.A. Davolt, M.J. Brakora, P.J. Sheffield, A.T. Porter: Does hyperbaric oxygen have a cancer-causing or -promoting effect? *Undersea Hyperbaric Med* 21 (1994), 467-475.

Feldmeier, J.J., R.D. Heimbach, D.A. Davolt, W.S. Court, B.J. Stegman, P.J. Sheffield: Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. *Undersea Hyperbaric Med* 23 (1996), 205-213.

Granström, G., M. Jacobsson, A. Tjellström: Titanium implants in irradiated tissue: benefits from hyperbaric oxygen. *J Oral Maxillofac Impl.* 7 (1992), 15-25

Hartmann, A., M. Almeling, U.M. Carl: Hyperbare Oxigenierung (HBO) zur Behandlung radiogener Nebenwirkungen. *Strahlenth. Onkol.* 172 (1996), 641-648.

Hobson, B., J. Denekamp: Endothelial proliferation in tumours and normal tissues: continuous labelling studies. *Br J Cancer* 49 (1984), 405-413.

Hopewell, J.W.: The late vascular effects of irradiation. *Br J Radiol* 47 (1974), 157-158.

Marx, R.E.: Osteoradionecrosis. A new concept of its pathophysiology. *J Oral Maxillofac surg* 41 (1983), 283-288

Marx, R.E., R.P. Johnson, S.N. Kline: Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. *J Am Dent Assoc* 111 (1985), 49-54.

Marx, R.E., R.P. Johnson: Studies in the radiobiology of osteoradionecrosis and their clinical significance. *Oral Surg Oral Med Oral Pathol* 64 (1987), 379-390.

Marx, R.E., W.J. Ehler, P. Tayapongsak, L.W. Pierce: Relationship of oxygen dose to angiogenesis induction in irradiated tissues. *Am J Surg* 160 (1990), 519-524.

Merkesteyn, J.P.R., D.J. Bakker, A.M.M.J. Borgmeijer-Hoelen: Hyperbaric oxygen treatment of osteoradionecrosis of the mandible. Experience in 29 patients. Oral Surg Oral Med Oral Pathol 80 (1995), 12-16.

Mounsey, R.A., D.H. Brown, T.P. O'Dwyer, P.J. Gullane, G.H. Koch: Role of hyperbaric oxygen therapy in the management of mandibular osteoradionecrosis. Laryngoscope 103 (1993), 605-608.

Neurath, M.F., A. Banbrink, K.-H. Meyer zum Büschenfelde, A.W. Lohse: A new treatment for severe malabsorption due to radiation enteritis. Lancet 347 (1996), 1302.

Sminia, P.: Diversion of radiation injury to late responding normal tissues by hyperbaric oxygen therapy? In Carl, U.M.(ed.): Proceedings „Hyperbaric oxygen in radiation therapy: where do we stand? Archimedes Verlag, Kiel-Strande (1996).

Thews, O., D.K. Kelleher, P. Vaupel: Hyperbaric oxygen of experimental tumors. Strahlenther Onkol 172; Suppl II (1996), 24-25.

Thiel, H.J.: Die Osteoradionekrose. Teil II: Therapie und Prävention. Radiobiol Radiother 30 (1989), 493-501.

Welslau, W., M. Almeling: Toxicity of hyperbaric oxygen (HBO)-Incidence of major CNS-intoxications. Strahlenther Onkol 172; Suppl II (1996),10-11.

Wittekind, C., A. Tannapfel: Die Entstehung von Metastasen und ihre Klassifikation. Strahlenther Onkol 172 (1996), 287-294.

Die Zusammenstellung basiert dazu auf Vorlagen von:

- PD Dr. med. U.M. Carl, Klinik für Strahlentherapie, Heinrich Heine Universität
- Düsseldorf, Moorenstr. 5, 40225 Düsseldorf
- Prof. Dr. G. Granström, Sahlgrenska Universitétshospital, Göteborg, Schweden
- Zusammenfassende Übersicht (reader) VDD

Hyperbaric oxygen therapy for late radiation tissue injury (Review)

Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C



**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2007, Issue 4

<http://www.thecochranelibrary.com>



TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	2
OBJECTIVES	3
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW	3
SEARCH METHODS FOR IDENTIFICATION OF STUDIES	4
METHODS OF THE REVIEW	4
DESCRIPTION OF STUDIES	6
METHODOLOGICAL QUALITY	7
RESULTS	7
DISCUSSION	9
AUTHORS' CONCLUSIONS	10
POTENTIAL CONFLICT OF INTEREST	11
ACKNOWLEDGEMENTS	11
SOURCES OF SUPPORT	11
REFERENCES	11
TABLES	13
Characteristics of included studies	13
Characteristics of excluded studies	15
ADDITIONAL TABLES	15
Table 01. The LENT-SOMA Scales - Conceptual summary	15
Table 02. Search Strategies	15
ANALYSES	16
Comparison 02. Complete resolution of problem	16
Comparison 03. Improvement in mean LENT-SOMA score	16
Comparison 04. Resolution of pain	16
Comparison 05. Resolution of swelling	17
Comparison 06. Improvements in quality of life or function	17
Comparison 07. Osteoradionecrosis	17
Comparison 11. Head and Neck	17
Comparison 12. Neurological tissue	17
INDEX TERMS	18
COVER SHEET	18
GRAPHS AND OTHER TABLES	19
Analysis 02.01. Comparison 02 Complete resolution of problem, Outcome 01 Complete resolution of clinical problem at three months	19
Analysis 02.02. Comparison 02 Complete resolution of problem, Outcome 02 Sensitivity analysis for missing data in proctitis (best case)	20
Analysis 02.03. Comparison 02 Complete resolution of problem, Outcome 03 Sensitivity analysis for missing data in proctitis (worst case)	20
Analysis 03.01. Comparison 03 Improvement in mean LENT-SOMA score, Outcome 01 Mean LENT-SOMA score at three months	21
Analysis 04.01. Comparison 04 Resolution of pain, Outcome 01 Pain score change at end of treatment	21
Analysis 04.02. Comparison 04 Resolution of pain, Outcome 02 Pain score change at one year	21
Analysis 05.01. Comparison 05 Resolution of swelling, Outcome 01 Improvement of lymphoedema	22
Analysis 06.01. Comparison 06 Improvements in quality of life or function, Outcome 01 SF-36 mean score at twelve months (general health)	22
Analysis 06.02. Comparison 06 Improvements in quality of life or function, Outcome 02 SF-36 mean score for physical function at 12 months	22
Analysis 07.01. Comparison 07 Osteoradionecrosis, Outcome 01 Complete mucosal cover	23
Analysis 07.02. Comparison 07 Osteoradionecrosis, Outcome 02 Establishment of bony continuity	23

Analysis 07.03. Comparison 07 Osteoradionecrosis, Outcome 03 Successful healing of tooth sockets after tooth extraction	24
Analysis 11.01. Comparison 11 Head and Neck, Outcome 01 Wound dehiscence	24
Analysis 12.03. Comparison 12 Neurological tissue, Outcome 03 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline)	25
Analysis 12.04. Comparison 12 Neurological tissue, Outcome 04 Warm sensory threshold at one year	25
Analysis 12.06. Comparison 12 Neurological tissue, Outcome 06 Net number of significantly improved neuropsychological tests at three months (25 tests total)	25
Analysis 12.07. Comparison 12 Neurological tissue, Outcome 07 Net number of significantly improved neuropsychiatric tests at six months	26

Hyperbaric oxygen therapy for late radiation tissue injury (Review)

Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C

This record should be cited as:

Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. *Cochrane Database of Systematic Reviews* 2005, Issue 3. Art. No.: CD005005. DOI: 10.1002/14651858.CD005005.pub2.

This version first published online: 20 July 2005 in Issue 3, 2005.

Date of most recent substantive amendment: 23 May 2005

A B S T R A C T

Background

Cancer is a significant global health problem. Radiotherapy is a treatment for many cancers and about 50% of patients having radiotherapy will be long-term survivors. Some will experience LRTI developing months or years later. HBOT has been suggested for LRTI based upon the ability to improve the blood supply to these tissues. It is postulated that HBOT may result in both healing of tissues and the prevention of problems following surgery.

Objectives

To assess the benefits and harms of HBOT for treating or preventing LRTI.

Search strategy

We searched The Cochrane Central Register of Controlled Trials (CENTRAL) Issue 3, 2004, MEDLINE, EMBASE, CINAHL and DORCTHIM (hyperbaric RCT register) in September 2004.

Selection criteria

Randomised controlled trials (RCTs) comparing the effect of HBOT versus no HBOT on LRTI prevention or healing.

Data collection and analysis

Three reviewers independently evaluated the quality of the relevant trials using the guidelines of the Cochrane Handbook (Clarke 2003) and extracted the data from the included trials.

Main results

Six trials contributed to this review (447 participants). For pooled analyses, investigation of heterogeneity suggested important variability between trials. From single studies there was a significantly improved chance of healing following HBOT for radiation proctitis (relative risk (RR) 2.7, 95% confidence interval (CI) 1.2 to 6.0, $P = 0.02$, numbers needed to treat (NNT) = 3), and following both surgical flaps (RR 8.7, 95% CI 2.7 to 27.5, $P = 0.0002$, NNT = 4) and hemimandibulectomy (RR 1.4, 95% CI 1.1 to 1.8, $P = 0.001$, NNT = 5). There was also a significantly improved probability of healing irradiated tooth sockets following dental extraction (RR 1.4, 95% CI 1.1 to 1.7, $P = 0.009$, NNT = 4).

There was no evidence of benefit in clinical outcomes with established radiation injury to neural tissue, and no data reported on the use of HBOT to treat other manifestations of LRTI. These trials did not report adverse effects.

Authors' conclusions

These small trials suggest that for people with LRTI affecting tissues of the head, neck, anus and rectum, HBOT is associated with improved outcome. HBOT also appears to reduce the chance of osteoradionecrosis following tooth extraction in an irradiated field. There was no such evidence of any important clinical effect on neurological tissues. The application of HBOT to selected patients and tissues may be justified. Further research is required to establish the optimum patient selection and timing of any therapy. An economic evaluation should be also be undertaken. There is no useful information from this review regarding the efficacy or effectiveness of HBOT for other tissues.

PLAIN LANGUAGE SUMMARY

Hyperbaric oxygen (HBO) may improve radiation injuries of the head, neck and bowel. It also appears to reduce the chance of bone death following tooth extraction.

There is a risk of serious complications developing after radiation treatment for cancer (late radiation tissue injury (LRTI)). Hyperbaric oxygen therapy (HBOT) involves breathing oxygen in a specially designed chamber. It is used as a treatment to improve oxygen supply to damaged tissue and stimulate healing. We found some evidence that LRTI affecting the head, neck and lower end of the bowel can be improved with HBOT. There is little evidence for or against benefit in other tissues affected by LRTI. Our conclusions are based on six randomised trials with a limited number of patients. Further research is needed.

BACKGROUND

Cancer is a significant global health problem. According to World Health Organization statistics, more than 10 million people are diagnosed with cancer every year, and it is estimated there will be 15 million new cases every year by 2020. Cancer causes 6 million deaths every year or 12% of deaths worldwide (WHO 2004). Radiotherapy is a well-established treatment of suitable malignancies in a wide variety of anatomical areas. Of the approximately 1.2 million new cases of invasive cancer diagnosed annually in the USA, for example, about 50% will receive radiation therapy (Jemal 2002), and of these, about 50% will be long-term survivors. While radiation therapy may acutely injure any normal tissue in the path of the radiation, this acute injury generally resolves following completion of the treatment course. Serious, radiation-related complications developing months or years after radiation treatment, collectively known as late radiation tissue injury (LRTI), are relatively rare and will significantly affect between 5% and 15% of those long-term survivors who received radiation therapy, although the incidence varies widely with dose, age and site (Rubin 1968; Stone 2003; Thompson 1999; Waddell 1999). Although any tissue may be affected, LRTI is in practice most common in the head and neck, chest wall, breast and pelvis - reflecting the anatomical areas most commonly irradiated and the likelihood of survival for patients treated for cancer at these anatomical sites.

When late radiation injuries occur, tissues undergo a progressive deterioration characterised by a reduction in the density of small blood vessels (reduced vascularity) and the replacement of normal tissue cells with dense fibrous tissue (fibrosis), until there is insufficient oxygen supplied to sustain normal function. This situation is frequently exacerbated by secondary damage due to infection or surgery in the affected area (Rubin 1984). This progressive and delayed radiation damage may reach a critical point where the tissue breaks down to form an ulcer or area of cell death (radiation necrosis, or radionecrosis). LRTI can affect any organ system, although some tissues are more sensitive to radiation effects than others (Thompson 1999; Trott 1984; Waddell 1999).

Historically, the management of these injuries has been unsatis-

factory. LRTI may be life threatening and may significantly re-

duce quality of life. Conservative treatment is usually restricted to symptom management, while definitive treatment traditionally entails surgery to remove the affected part and extensive repair (Stone 2003). Surgical intervention in an irradiated field is often disfiguring and associated with an increased incidence of delayed healing, breakdown of a surgical wound or infection.

HBOT has been proposed to improve tissue quality, promote healing and prevent breakdown of irradiated tissue fields. It may be defined as the therapeutic administration of 100% oxygen at environmental pressures greater than one atmosphere absolute (ATA). Administration involves placing the patient in an airtight vessel, increasing the pressure within that vessel, and giving 100% oxygen for respiration. In this way, it is possible to deliver a greatly increased pressure of oxygen to the lungs, blood and tissues. Typically, treatments involve pressurisation to between 2.0 and 2.5 ATA for periods between 60 and 120 minutes once or twice daily to a total of 30 to 60 sessions of treatment.

The intermittent application of HBO is the only intervention that has been shown to increase the number of blood vessels in irradiated tissue. This has been demonstrated by Marx in a rabbit mandibular (jaw bone) model and further confirmed by serial tissue oxygen level measurements using electrodes placed on the overlying skin (transcutaneous oximetry) in humans undergoing a course of therapy for radiation necrosis of the mandible (Marx 1988; Marx 1990). In the rabbit study, the jaw and surrounding soft tissues were heavily irradiated and one group 'rescued' with HBO six months later. The 2 control groups showed no improvement while a series of 20 sessions at 2.4 atmospheres absolute (ATA) on 100% oxygen returned the density of blood vessels to 80% of normal. In the human study, a progressive recovery of low transcutaneous oximetry readings into the normal range was achieved in a group of patients receiving therapy for underlying osteoradionecrosis (radiation necrosis of bone).

HBOT seems most likely to achieve such improvements through a complex series of changes in affected tissues. Tissue swelling is probably improved through an osmotic effect of oxygen, while the establishment of a steep oxygen gradient across an irradiated tissue margin is a powerful stimulus to the growth of new blood vessels (Davis 1988; Hills 1999). In addition, improving oxygen

levels will improve white cell and fibroblast function, further enhancing wound healing (Mandell 1974). Improved tissue quality has been demonstrated in a model of radiation small bowel injury (Feldmeier 1995; Feldmeier 1998).

While HBOT has been used for LRTI since at least 1975 (Mainous 1975), most clinical studies have been limited to relatively small case series or individual case reports. There have been relatively few comparative studies published, and no previous quantitative systematic reviews of which we are aware. In a recent semi-quantitative review, Feldmeier and Hampson located 71 such reports involving a total of 1193 patients across 8 different tissues (Feldmeier 2002). In these patients, for whom conservative treatment had failed to improve symptoms, there were clinically significant improvements in the majority of patients. Results varied between tissue types, with neurological tissue appearing the most resistant to improvement. Only 7 of 71 reports indicated a generally poor response to HBOT. The present review will complement Feldmeier 2002 by using explicit Cochrane methodology to locate, quantitatively appraise and summarise the comparative data, while not discussing in any detail the non-comparative series summarised in that review.

HBOT is associated with some risk of adverse effects including damage to the ears, sinuses and lungs from the effects of pressure, temporary worsening of short sightedness (myopia), claustrophobia and oxygen poisoning. Although serious adverse events are rare, HBOT cannot be regarded as an entirely benign intervention. It has further been suggested that HBOT may increase the incidence and rate, or both of growth of tumours in patients with a history of malignancy. A recent comprehensive review fails to support these concerns (Feldmeier 2003).

OBJECTIVES

The objectives of this review were to determine the efficacy and safety of HBOT in the treatment of patients with late radiation tissue injury.

Specifically we addressed the following questions:

- Is a course of HBOT more efficacious than placebo or no treatment in improving symptoms, signs and disability for patients with LRTI?
- Is a course of HBOT more efficacious than placebo or no treatment in preventing further deterioration for patients with LRTI?
- Is HBOT administration safe?

Primary outcome measures:

Hyperbaric oxygen therapy for late radiation tissue injury (Review)

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

Types of studies

Randomised and pseudo-RCTs that compared the effect of a regimen including HBOT on any form of late radiation tissue injury, with any treatment regimen not including HBOT.

Types of participants

Any person with late radiation tissue injury (including necrosis) of whatever tissue. We also accepted patients treated with large dose radiation therapy likely to induce relatively early necrosis (e.g. radiosurgery to a brain lesion).

Types of intervention

We accepted trials comparing regimens which included HBOT with similar regimens that excluded HBOT. Where co-interventions differed significantly between studies this was clearly stated and the implications discussed.

The intervention under examination was HBOT administered in a compression chamber between pressures of 1.5 ATA and 4.0 ATA and treatment times between 30 mins and 120 mins daily or twice daily. These parameters exclude trivial treatments on the one hand, and highly toxic exposures on the other. The comparator group was diverse, and we accepted any standard treatment regimen designed to promote tissue healing or prevent further deterioration.

Types of outcome measures

Appropriate outcome measure depended on the nature of the LRTI and the anatomical location. Studies were eligible for inclusion if they reported any of the following outcome measures:

All anatomical areas

Primary outcome measures:

- (1) Survival
- (2) Complete resolution of necrosis or tissue damage
- (3) Improvement in LENT-SOMA scale

[The LENT-SOMA scales (Late Effects Normal Tissues - Subjective, Objective, Management, Analytic) were developed jointly by the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) in 1995 in order to standardise assessment of LRTI (Pavy 1995). Scales are location specific and have been summarised in a number of forms for each location. The implications for pooling are discussed as required. The scale dimensions are summarised in Table 01.]

Secondary outcome measures:

- (4) Resolution of pain
- (5) Resolution of swelling
- (6) Improvement in quality of life (QOL) and/or function
- (7) *Osteoradionecrosis (ORN)*

- (a) Healing with complete soft tissue coverage over bone
- (b) Resolution of sinus tract between bone and skin or mucosa
- (c) Resolution of fracture or re-establishment of bony continuity
- (d) Development of ORN in tooth socket following extraction

Secondary outcome measures:

- (e) Improvement in X-Ray appearance

(8) *Head and neck soft tissues*

Primary outcome measures:

- (a) Wound dehiscence (breakdown of a surgical wound)
- (b) Surgical removal of larynx
- (c) Major vessel bleeding

Secondary outcome measures:

- (d) Speed of wound healing
- (e) Improvement in swelling or 'woodiness' of tissue
- (f) Reversal of tracheostomy (surgical breathing hole in the trachea)

(9) *Urinary bladder*

Primary outcome measures:

- (a) Resolution of bleeding
- (b) Removal of bladder and urine diversion procedures

Secondary outcome measures:

- (c) Improved cystoscopic appearance
- (d) Frequency
- (e) Dysuria (pain on passage of urine)

(10) *Chest wall*

Nil additional to those listed under 'All anatomical areas'.

(11) *Bowel*

Primary outcome measures:

- (a) Resolution of bleeding
- (b) Operations on the bowel such as colostomy, ileostomy or bowel resection

Secondary outcome measures:

- (c) Improvement in pain score

(12) *Neurological tissue*

Primary outcome measures:

- (a) Improvement in objective motor function
- (b) Improvement in visual acuity

Secondary outcome measures:

- (c) Improvement in sensory function
- (d) Improvement in functional ability or activities of daily living
- (e) Improvement in neuropsychiatric testing
- (f) Improvement in X-ray or scan appearance
- (g) Reduction in steroid dose

Extremities

Nil additional to those listed under 'All anatomical areas'.

Adverse events of HBOT

- (a) Recurrence of tumour (locally or remote)
- (b) Visual disturbance (short and long term)
- (c) damage from pressure (aural, sinus or pulmonary barotrauma, in the short and long-term)
- (d) Oxygen toxicity (short-term)
- (e) Withdrawal from treatment for any reason
- (f) Any other recorded adverse effect

SEARCH METHODS FOR IDENTIFICATION OF STUDIES

See: methods used in reviews.

It was our intention to capture both published and unpublished studies.

Electronic searches

We searched: CENTRAL (The Cochrane Library August 2004), MEDLINE (1966 to August 2004), EMBASE (1980 to August 2004), CINAHL (1982 to August 2004) and an additional database developed in our hyperbaric facility, The Database of Randomised Trials in Hyperbaric Medicine (Bennett 2004). The search strategy was broad and the keywords in the following strategies were adapted as appropriate. The EMBASE and MEDLINE (OVID) strategies are given in Table 02.

In addition we made a systematic search for relevant controlled trials in specific hyperbaric literature sources as follows.

- Experts in the field and leading hyperbaric therapy centres (as identified by personal communication and searching the Internet) were contacted and asked for additional relevant data in terms of published or unpublished randomized trials.
- Handsearch of relevant hyperbaric textbooks (Kindwall, Jain, Marroni, Bakker, Bennett and Elliot), journals (Undersea and Hyperbaric Medicine, Hyperbaric Medicine Review, South Pacific Underwater Medicine Society (SPUMS) Journal, European Journal of Hyperbaric Medicine and Aviation, Space and Environmental Medicine Journal) and conference proceedings (Undersea and Hyperbaric Medical Society, SPUMS, European Undersea and Baromedical Society, International Congress of Hyperbaric Medicine) published since 1980.
- Contacted of authors of relevant studies to request details of unpublished or ongoing investigations.
- Examination of the reference list of all trials for inclusion in this review.

All languages were considered. Authors were contacted if there was any ambiguity about the published data.

METHODS OF THE REVIEW

Data retrieval and management

One reviewer (MB) was responsible for handsearching and identification of appropriate studies for consideration and all possibly relevant studies were entered into a bibliographic software package (Review Manager). Three reviewers (MB, JF and NH) then examined the electronic search results and identified comparative studies that may have been relevant. Studies were retained when one or more reviewers identified them as appropriate. Retained studies were retrieved in full and reviewed independently by three reviewers, all with content expertise in HBOT, one with content expertise in radiation oncology (JF). In addition one of the reviewers (MB) has expertise in clinical epidemiology. Reviewers recorded data using the data extraction form developed for this review.

Data extraction

Each reviewer independently extracted the relevant data. Primary authors were contacted to provide information when missing data was encountered or if necessary data such as adverse events were not clearly stated. All differences were resolved by discussion among the reviewers and no disputed trials required referral to the Review Group contact editor for appraisal.

Quality assessment

Study quality was assessed using an adaptation of the method outlined in Schulz (Schulz 1995), and recommendations made for inclusion or exclusion from the review. Results from the study quality assessment are presented in a descriptive manner. The following characteristics were assessed:

Adequacy of the randomization process:

- A - Adequate sequence generation is reported using random number tables, computer random number generator, coin tossing, or shuffling;
- B - Did not specify one of the adequate reported methods in (A) but mentioned randomization method;
- C - Other methods of allocation that appear to be unbiased.

Adequacy of the allocation concealment process:

- A - Adequate measures to conceal allocations such as central randomization; serially numbered, opaque, sealed envelopes; or other description that contained convincing elements of concealment;
- B - Unclearly concealed trials in which the author either did not report an allocation concealment approach at all, or reported an approach that did not fall into one of the categories in (A);
- C - Inadequately concealed trials in which method of allocation is not concealed such as alternation methods or use of case record numbers.

Potential for selection bias after allocation:

- A- Trials where an intention-to-treat analysis is possible and few losses to follow-up are noted;
- ~~B- Trials which reported exclusions (as listed in A but exclusions~~

were less than 10%);

C- No reporting on exclusions or exclusions greater than 10% or wide differences in exclusions between groups.

Level of masking (treatment provider, patient, outcome assessor):

- A- Double or triple-blind;
- B- Single-blind;
- C- Non-blind.

These four factors were considered for possible sensitivity analysis.

Analyses

It was our intention where possible to analyse the data from different anatomical sites together (see outcomes listed under 'all anatomical areas'). However, many outcomes are specific to a particular anatomical site, and these outcomes were analysed separately. All comparisons were made using an intention-to-treat analysis where possible and reflect efficacy in the context of randomized trialling, rather than true effectiveness in any particular clinical context. While we planned to compare survival over time using the log Hazard Ratio and variance (Parmar 1998), no suitable data was available. For dichotomous outcomes RR was used. For continuous data, the mean difference (MD) between treatment and control arms in each trial was calculated and aggregated using inverse variance weights to estimate an overall MD and its 95% CI. We used a fixed-effect model where there was no evidence of significant clinical heterogeneity between studies (see below), and employed a random effects model when such heterogeneity was likely. All statistical analysis was performed using RevMan software.

Where co-interventions differed significantly between studies this was clearly stated and the implications discussed.

Overall primary outcomes (All anatomic areas):

(1) Survival. For each trial, we calculated the RR for survival in the HBOT group compared to the control group. These RRs were pooled in a meta-analysis to estimate an overall RR and its 95% CI. A statistically significant difference between experimental intervention and control intervention was assumed if the 95% CI of the RR did not include the value 1.0. As an estimate of the clinical relevance of any difference between experimental intervention and control intervention, we calculated the number needed to treat (NNT) and number needed to harm (NNH) with 95% CI as appropriate, using the formula $NNT = 1/RR$ with 95% CI calculated from the 95% CI of the RR, following the method recommended in Altman 2001.

(2) Complete resolution of necrosis or tissue damage. The RR for complete resolution of necrosis or tissue damage with and without HBOT was calculated using the methods described in (1) above.

(3) Improvement in LENT-SOMA scales. For each trial, the mean difference (MD) in this score between HBOT and control groups was to be calculated and combined in a meta-analysis to estimate an overall MD and its 95% CI. No trials reported this outcome.

Overall secondary outcomes:

(4) Radiological improvement. Statistical analysis would depend on the nature of the data, but would have followed the methods outlined above. No trials reported this outcome.

The outcomes for each anatomical site will be approached in an analogous manner to that outlined above.

(5) Adverse events . For each trial, we planned to calculate the RR for each adverse event in the HBOT compared to the control group. These RRs were to be pooled in a meta-analysis to estimate an overall RR and its 95% CI. No trials reported this outcome.

Sensitivity analyses

We intended to perform sensitivity analyses for missing data and study quality where appropriate.

Missing data

We employed sensitivity analyses using different approaches to imputing missing data. The best-case scenario assumed that none of the originally enrolled patients missing from the primary analysis in the treatment group had the negative outcome of interest whilst all those missing from the control group did. The worst case scenario was the reverse.

Study quality

If appropriate, we had planned to conduct a sensitivity analysis by study quality based on the presence or absence of a reliable random allocation method, concealment of allocation and blinding of participants or outcome assessors.

Heterogeneity

Heterogeneity was assessed using the I^2 statistic and consideration given to the appropriateness of pooling and meta-analysis.

Subgroups

We considered subgroup analysis based on:

- Anatomical location
- Dose of oxygen received (pressure, time and length of treatment course)
- Nature of the comparative treatment modalities
- Severity of injury

DESCRIPTION OF STUDIES

We identified 103 publications apparently dealing with the use of HBOT for the treatment of LRTI. Initial examination confirmed 62 were case reports or case series, 25 were reviews or letters without new data, one was a report of a planning workshop and one was a report of animal work. These reports were excluded, leaving 14 possible randomised comparative trials. After appraisal of the full reports we further excluded five reports with non-

random controls (Carl 2001; Gal 2003; Granstrom 1999; Maier 2000;

Niimi 1997), two systematic reviews (Coulthard 2002; Denton 2002) with no further randomised data and one randomised trial with no quantitative data (Tobey 1979). See table 'Characteristics of excluded studies'. The other six trials were accepted into the review (Clarke 2004; Hulshof 2002; Marx 1985; Marx 1999a; Marx 1999b; Pritchard 2001). Marx 1999a and Marx 1999b are trials reported for the first time in a textbook. The recruitment period for these studies is not known.

The included trials were published between 1985 and 2004, and the reviewers are aware that there is a large, multicentre trial underway into the effect of HBOT on eight different manifestations of LRTI. Clarke 2004 is the first brief report of one arm of that trial. In total, these trials include data on 447 participants, 224 receiving HBOT and 223 control. The largest (Marx 1999b) accounts for 36% of cases. (See Table: 'Characteristics of included studies').

Where sex was specified, the trials enrolled more females than males (Pritchard 2001 enrolled 34 participants, all female; Hulshof 2002 six females and one male). With regard to age, Pritchard 2001 enrolled participants from age 40 to 79 years and in Hulshof 2002 the average age was 46 years. Two studies did not specify any such characteristics except prior exposure to 6400 cGy in the area under investigation (Marx 1999a; Marx 1999b). The other four studies specified exclusion of those unfit for compression or the presence of residual tumour, while Marx 1985 also excluded those with penicillin sensitivity, recent chemotherapy or concurrent disease known to effect wound healing . No details of prior therapy for the pathology under study were given, while Marx 1985 specified a minimum prior radiation dose of 6000 cGy at least six months prior to enrollment. Clarke 2004 entered participants with radiation proctitis, Hulshof 2002 those with cognitive deficits following brain irradiation with at least 30 Gy, Pritchard 2001 radiation-induced brachial plexus lesions, Marx 1999a candidates for hemimandibular jaw reconstruction, Marx 1999b candidates requiring major soft tissue surgery or flaps, and Marx 1985 participants requiring tooth extraction.

Both the dose of oxygen per treatment session and for the total course of treatment varied between studies. The lowest pressure administered was 2.0 ATA (Clarke 2004) and the highest 3.0 ATA (Hulshof 2002), while all other trials utilised 2.4 ATA. Treatment periods for each session ranged from 90 minutes (Marx 1985; Marx 1999a; Marx 1999b) to 120 minutes (Clarke 2004). All trials administered a total of 30 treatments except Clarke 2004, where there was an option to continue to 40 treatments.

Marx 1985 involved a comparator treatment of penicillin for 10 days, while there were no active comparator regimens in the other trials. Two trials administered a blinded sham therapy (Clarke

2004; Pritchard 2001) Details are given in the table 'Characteristics of included studies'.

The follow-up periods varied between three weeks following the treatment course (Marx 1999b), three months (Clarke 2004), six months (Hulshof 2002; Marx 1985) and one year (Pritchard 2001). Marx 1999a did not specify the time at which outcome was measured. All included studies reported at least one clinical outcome of interest. Of the outcomes identified above, these trials reported data on primary outcomes (resolution of problem, bony continuity established, wound dehiscence and LENT-SOMA scale) and secondary outcomes (oedema resolution, pain scores, QOL, physical functioning, sensory function and neuropsychiatric testing).

Other outcomes (including non-clinical) reported included: self-rated memory and dexterity (Hulshof 2002), sensory action potentials (Pritchard 2001), post-surgical complication rate (Marx 1999a) and wound infection rate (Marx 1999b).

METHODOLOGICAL QUALITY

Details of the quality assessment are given in the table 'Characteristics of included studies'. Study quality varied widely, however, because very few analyses could be pooled, study quality was not used as a basis for sensitivity analysis. Although Clarke 2004 is an abstract only, this trial is known to the reviewers and many details have been provided through personal communication.

Allocation concealment

Allocation concealment was adequately described in three studies (Clarke 2004; Hulshof 2002; Pritchard 2001), all three using a remotely located randomisation officer. For none of the remaining studies is there a clear indication that the investigators were unable to predict the prospective group to which a participant would be allocated.

Randomisation

Randomisation procedures were described in two studies (Clarke 2004; Pritchard 2001), both employing a computer generated random number table, but not in the other four.

Subject baseline characteristics

Given the variation in pathology outlined in 'Description of Studies' above, it is not surprising that there is considerable variation in patient baseline characteristics. Two studies did not specify any baseline characteristics except prior exposure to 6400 cGy in the area under investigation (Marx 1999a; Marx 1999b). The other four studies specified exclusion of those unfit for compression. No details of prior therapy for the pathology under study were given, while Marx 1985 specified a minimum prior radiation dose of 6000 cGy at least six months prior to enrollment.

Blinding

Two studies utilised a sham therapy in order to mask subjects and outcome assessors to HBOT (Clarke 2004; Pritchard 2001),

while

no sham was employed in the remaining four studies (Hulshof 2002; Marx 1985; Marx 1999a; Marx 1999b). No author formally tested the success of their blinding strategy.

Patients lost to follow-up

Five studies did not report any losses to follow-up or violation of the study protocol (Hulshof 2002; Marx 1985; Marx 1999a; Marx 1999b; Pritchard 2001). Clarke 2004 lost seven control subjects and four HBOT group subjects, and these subjects were excluded from the analysis reported in the abstract. Sensitivity analysis using best and worst case scenarios were performed where this study contributed data to the analysis.

Intention-to-treat analysis

Only Pritchard 2001 specifically detailed an intention to treat analysis (two subjects in the HBOT group did not complete therapy, but were included in analysis). Four of the remaining five studies reported full follow-up and did not report any protocol violation (see above).

RESULTS

Combined anatomical areas

Primary outcomes

(1) Death (comparison 01) No trial reported any data on this outcome.

(2) Complete resolution of tissue damage or necrosis (comparison 02)

(a) Complete resolution of clinical problem at three months (comparison 02, outcomes 01, 02, 03)

Three trials reported this outcome (Clarke 2004; Marx 1999a; Pritchard 2001), involving 172 participants (39% of the total participants in this review), with 86 randomised to both HBOT and control arms. Overall, 64 (74%) of participants in the HBOT arm achieved resolution, versus 40 (47%) in the control group. Analysis for heterogeneity suggested a high proportion of variability between trials was not due to sampling variability ($I^2 = 65\%$), and so this comparison was made using a random effects model with stratification by tissue type involved (other subgroup analyses did not separate these studies). Further, one study (Pritchard 2001) did not report any participants with resolution, so could not contribute to the analysis.

There was a significantly improved probability of resolution with the administration of HBOT for both radiation proctitis (RR 2.7, 95% CI 1.2 to 6.0, $P = 0.02$) (Clarke 2004), and hemimandibulectomy (RR 1.4, 95% CI 1.1 to 1.8, $P = 0.001$, (Marx 1999a). The result for proctitis was however, sensitive to the allocation of dropouts (best case: RR 3.3, 95% CI 1.5 to 7.3, $P = 0.002$; worst case: RR 1.2, 95% CI 0.7 to 2.2, $P = 0.4$). For proctitis, 16 participants (47%) achieved resolution of their problem following HBOT versus six participants (18%) in the control group;

suggesting the number needed to treat with HBOT to achieve one extra subject with a resolved problem was 3, (95% CI 2 to 11).

For participants requiring hemimandibulectomy, 48 participants (92%) achieved resolution following HBOT versus 34 (65%) in the control group, NNT 4, (95% CI 2 to 8).

(3) LENT-SOMA scores (comparison 03)

(a) Improvement in LENT-SOMA score at three months

Only one trial reported this outcome (Clarke 2004) involving 68 subjects (15% of the total), with 34 randomised to both HBOT and control. The mean improvement in LENT-SOMA score was greater in the HBOT group (4.7 versus 0.73), and this difference was statistically significant (WMD 4.0, 95% CI 1.7 to 6.3, P = 0.0007).

Secondary outcomes

(4) Pain scores (comparison 04)

(a) Change in pain score (0 to 100 scale) from baseline to six months after treatment (comparison 04, outcome 01)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. Pain scores increased over this time period in both groups, but more so with HBOT (5.3 points versus 1.2). Standard deviations were not reported around these means, precluding further analysis.

(b) Change in pain score (0 to 100 scale) from baseline to 12 months after treatment (comparison 04, outcome 02)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. Pain scores were reduced in both groups, but more so in the controls (-5.0 points versus -0.7). Standard deviations were not reported around these means, precluding further analysis.

5. Swelling (comparison 05)

(a) Resolution of lymphoedema in arm at six months (comparison 05, outcome 01)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. Two subjects (12%) in the HBOT arm achieved resolution, while none in the control group did so. This difference in favour of HBOT was not statistically significant (RR of resolution with HBOT 5.0, 95% CI 0.3 to 97.0, P = 0.29).

(6) Quality of life or functional scores (comparison 06)

(a) SF-36 score for general health at 12 months (comparison 06, outcome 01)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. The mean score for general health self-rating was lower in the HBOT group (58.8 versus 61.1), but not significantly so (WMD -2.3, 95% CI -19.0 to 14.4, P = 0.79).

(b) 2 SF-36 score for physical functioning at 12 months (comparison 06, outcome 02)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. The mean score for self-rating of physical functioning was lower in the HBOT group (53.5 versus 57.5), but not significantly so (WMD -4.0, 95% CI -19.4 to 11.4, P = 0.61).

(7) Osteoradionecrosis

Primary outcomes

(a) Achievement of complete mucosal cover (comparison 07, outcome 01)

Two trials reported this outcome (Marx 1985; Marx 1999a), involving 178 subjects (40% of the total), with 89 randomised to both HBOT and control arms. Eighty three (93%) of subjects in the HBOT arm achieved resolution, versus 60 (67%) in the control group. Heterogeneity did not appear to be a problem with this analysis ($I^2 = 0\%$). There was a significantly improved probability of attaining mucosal cover with the administration of HBOT (RR 1.4, 95% CI 1.2 to 1.6, P < 0.001). The NNT to achieve one further case with mucosal cover with the application of HBOT is 4, (95% CI 2 to 8).

(b) Resolution of sinus tract (comparison 07, outcome 03)

No study reported data on this outcome

(c) Establishment of bony continuity (comparison 07, outcome 02)

Only one trial contributed results to this outcome (Marx 1995a) involving 104 subjects (23% of the total), 52 randomised to both HBOT and control. Forty eight (92%) of subjects in the HBOT arm achieved continuity, versus 60 (65%) in the control group. There was a significantly improved probability of attaining bony continuity with the administration of HBOT (RR 1.4, 95% CI 1.1 to 1.8, P = 0.001). The NNT to achieve one further case with bony continuity with the application of HBOT is 4, (95% CI 2 to 8).

(d) Healing of tooth sockets following extraction in irradiated field at six months (comparison 07, outcome 03)

Only one trial contributed results to this outcome (Marx 1985) involving 74 subjects (17% of the total), 37 randomised to both HBOT and control. 35 (95%) of subjects in the HBOT arm achieved healing of all sockets, versus 26 (70%) in the control group. There was a significantly improved probability of healing with the administration of HBOT (RR 1.4, 95% CI 1.1 to 1.7, P = 0.009). The NNT with HBOT to achieve one further case with all tooth sockets healed is 4, (95% CI 2 to 13).

Secondary outcomes

(e) Improvement in X-Ray appearance (comparison 07, outcome 05)

No study reported data on this outcome.

8. Head and neck tissues

Primary outcomes

(a) Wound dehiscence (comparison 08, outcome 01)

Two trials reported this outcome (Marx 1999a; Marx 1999b), involving 132 subjects (60% of the total subjects in this review), with 132 randomised to both HBOT and control arms. Overall,

8 (6%) subjects in the HBOT arm suffered wound breakdown, versus 37 (28%) in the control group. Analysis for heterogeneity suggested a high proportion of variability between trials was not due to sampling variability ($I^2=70\%$), and so this comparison was made using a random effects model. There was a significantly improved chance of wound breakdown with control (RR 4.2, 95% CI 1.1 to 16.8, $P = 0.04$). Stratification by tissue type involved confirmed the direction of effect was the same for both studies, but it remained significant only for soft tissue flaps and grafts (RR following hemimandibulectomy (Marx 1999a) 2.2, 95% CI 0.8 to 5.9, $P = 0.12$; RR following soft tissue flap or graft (Marx 1999b) 8.7, 95% CI 2.7 to 27.5, $P = 0.0002$). The number needed to treat with HBOT to avoid one wound dehiscence overall was 5 (95% CI 1 to 59), and for soft tissue repairs alone was 4 (95% CI 3 to 6).

(b) Surgical removal of the larynx (comparison 08, outcome 02)
No study reported data on this outcome.

(c) Major bleeding (comparison 08, outcome 03)
No study reported data on this outcome.

Secondary outcomes

(d) Speed of wound healing (comparison 08, outcome 04)
No study reported data on this outcome.

(e) Improvements in tissue quality (comparison 08, outcome 05)
No study reported data on this outcome.

(f) Reversal of tracheostomy (comparison 08, outcome 06)
No study reported data on this outcome.

(9) Urinary bladder (comparison 9)
No study reported data on outcomes for this tissue.

(10) Chest wall (comparison 10)
No study reported data on outcomes for this tissue.

(11) Bowel (comparison 11)
No study reported data on outcomes for this tissue.

(12) Neurological tissue (comparison 12)
Primary outcomes

(a) Objective motor function (comparison 12, outcome 01)
No study reported data on this outcome.

(b) Visual acuity (comparison 12, outcome 02)
No study reported data on this outcome.

Secondary outcomes

(c) Warm sensory threshold at one week after therapy (comparison 12, outcome 03)
Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. The mean threshold temperature for reporting a warm sensation at one week after therapy (compared to pretreatment baseline) was reduced in the HBOT group, but not in the con-

trols (-0.1 degree versus 1 degree). This difference was not statistically

significant (WMD 1.1 degrees lower, 95% CI -1.9 to 4.1, $P = 0.47$).

(d) Warm sensory threshold at one year after therapy (comparison 12, outcome 04)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (8% of the total) with 17 randomised to both HBOT and control. The mean threshold for reporting a warm sensation was increased in both groups, but less so in controls (0.5 degrees versus 1.4). This difference was not statistically significant (WMD 0.9 degrees, 95% CI -2.3 to 4.0, $P = 0.47$).

(e) Functional ability scores and ADL (comparison 12, outcome 05)

No study reported data on this outcome.

(f) Net number of neuropsychological tests (maximum 25 tests) improved at three months (comparison 12, outcome 06)

Only one trial reported this outcome (Hulshof 2002) involving seven patients (2% of the total) with four randomised to HBOT and three to control. The mean net number of improved tests was greater in the HBOT group (3.3 versus 1.3), but not significantly so (WMD 2, 95% CI -1.6 to 5.0, $P = 0.28$).

(g) Net number of neuropsychological tests (maximum 25 tests) improved at six months (comparison 12, outcome 06)

Only one trial reported this outcome (Hulshof 2002) involving seven patients (2% of the total) with four randomised to HBOT and three to control. The mean net number of improved tests was greater in the HBOT group (3 versus 2), but not significantly so (WMD 1.1, 95% CI -3.6 to 5.6, $P = 0.67$).

(13) Adverse events
No study reported data on these outcomes.

DISCUSSION

This review has included data from six trials investigating the use of HBOT for tissue suffering from late radiation damage, and we believe these represent all randomised human trials in this area, both published and unpublished, at the time of searching the databases. We found some evidence that HBOT improves the probability of healing in radiation proctitis and following hemimandibulectomy and reconstruction of the mandible; improves the probability of achieving mucosal coverage and the restoration of bony continuity with ORN; prevents the development of ORN following tooth extraction from a radiation field; and reduces the risk of wound dehiscence following grafts and flaps in the head and neck. Although there was some trend toward secondary favourable outcomes in neurological tissue, there was no evidence of benefit in important clinical outcomes with established radiation brachial plexus lesions or cerebral tissue injury. There was no data reported

from any randomised trials involving the use of HBOT to treat other manifestations of radiation tissue damage.

Only six trials with 447 participants were available for evaluation using our planned comparisons, and meta-analysis was not appropriate or possible for most of these. Many of the trials enrolled modest numbers of patients, particularly the trial investigating cerebral radiation injury, where only seven subjects were reported (Hulshof 2002). Other problems for this review were the poor methodological quality of some of these trials (particularly Marx 1999a; Marx 1999b), variability in entry criteria and the nature and timing of outcomes, and poor reporting of both outcomes and methodology. In particular, there is a possibility of bias in the combined tissue outcomes due to different anatomical locations and extent of tissue damage on entry to these trials, as well as from non-blinded management decisions in three of the trials (Marx 1985; Marx 1999a; Marx 1999b). Further, it is not clear when the subjects for Marx 1999a and Marx 1999b were recruited - these trials may represent work from some years earlier.

These trials were published over a 19-year period up to 2004, and from a wide geographical area. We had planned to perform subgroup analyses with respect to anatomical location, dose of oxygen received (pressure, time and length of treatment course), nature of the comparative treatment modalities and the severity of injury. However, the paucity of eligible trials and poor reporting of some trials suggested that except for anatomical location, these analyses would not be informative. The oxygen dose used was reasonably standard over most trials. Patient inclusion criteria were not standard, and poorly reported in some trials. Specific comparator therapies were generally not employed.

Three trials reported on complete resolution of the clinical problem (Clarke 2004; Marx 1999a; Pritchard 2001). Results varied widely and could not be pooled. Clarke 2004 and Marx 1999a reported significant improvement in the chance of healing radiation proctitis (RR 2.7, P = 0.02, NNT 4), and following hemimandibulectomy and reconstruction (RR 1.4, P = 0.001, NNT 4) respectively. Pritchard 2001, in contrast, reported no such resolution in any subject treated for established radiation brachial plexopathy. This difference in outcome could reflect the unresponsiveness of neurological tissue in general (an assertion supported by a similar lack of response for brain radiation injury in Hulshof 2002, or the relatively long-standing nature of the injuries enrolled in that trial (mean period from radiotherapy to HBOT was 11 years). The Clarke 2004 analysis was also sensitive to the allocation of dropouts and we await further reporting of this trial in full. Although this trial has only been reported in abstract, the author has provided considerable methodological detail in private correspondence for this review.

Pooling data for clinical outcomes of interest could only be performed with respect to the risk of wound dehiscence. This analysis suggested some benefit from HBOT administration (RR of dehiscence with control group was 4.2 [95% CI 1.1 to 16.8], NNT 5 [95% CI 3 to 8]). This result was subject to a high proportion of variability being due to differences between trials rather

than to sampling variability, and the two trials were of relatively low quality. It should be interpreted with great caution. This possible treatment effect is, however, of great clinical importance and deserves further investigation.

The incidence of adverse effects was not assessed by the studies included in this review. There are a number of minor complications that may occur commonly. Visual disturbance, usually reduction in visual acuity secondary to conformational changes in the lens, is very commonly reported - perhaps as many as 50% of those having a course of 30 treatments (Khan 2003). While the great majority of patients recover spontaneously over a period of days to weeks, a small proportion of patients continue to require correction to restore sight to pre-treatment levels. None of the trials included in this review reported visual changes. The second most common adverse effect associated with HBOT is middle-ear barotrauma. Barotrauma can affect any air-filled cavity in the body (including the middle ear, lungs and respiratory sinuses) and occurs as a direct result of compression. Ear barotrauma is by far the most common as the middle ear air space is small, largely surrounded by bone and the sensitive tympanic membrane, and usually requires active effort by the patient in order to inflate the middle ear through the eustachian tube on each side. Barotrauma is thus not a consequence of HBOT directly, but rather of the physical conditions required to administer it. Most episodes of barotrauma are mild, easily treated or recover spontaneously and do not require the therapy to be abandoned.

All of these findings are subject to a potential publication bias. While we have made every effort to locate further unpublished data, it remains possible that this review is subject to a positive publication bias, with generally favourable trials more likely to achieve reporting. With regard to long-term outcomes following HBOT and any effect on the QOL for these patients, we have located little relevant data.

AUTHORS' CONCLUSIONS

Implications for practice

There is some evidence that HBOT improves outcome in late radiation tissue injury affecting bone and soft tissues of the head and neck, for radiation proctitis and to prevent the development of osteoradionecrosis following tooth extraction in an irradiated field. There was no such evidence of any important clinical effect on neurological tissues, either peripheral or central. Thus, the application of HBOT to selected patients and tissues may be justified. The small number of studies, the modest numbers of patients and the methodological and reporting inadequacies of some of the primary studies included in this review demand a cautious interpretation. Further research is required to establish the optimum patient selection and timing of any such therapy. An economic evaluation should also be undertaken. There is no evidence of a benefit from

HBOT for the treatment of affected neurological tissue, and to date, no useful information regarding the efficacy or effectiveness of HBOT for other tissues can be provided.

Implications for research

There is a strong case for further large randomised trials of high methodological rigour in order to define the true extent of benefit from the administration of HBOT for patients with late radiation tissue injury. Specifically, more information is required on the subset of disease severity and tissue type affected that is most likely to benefit from this therapy, the time for which we can expect any benefits to persist, and the oxygen dose most appropriate. Any future trials would need to consider in particular:

Appropriate sample sizes with power to detect expected differences generated by this review

Careful definition and selection of target patients

Appropriate oxygen dose per treatment session (pressure and time)
Appropriate supportive therapy to which HBOT would be an adjunct

Use of an effective sham therapy

Effective and explicit blinding of outcome assessors

Appropriate outcome measures including all those listed in this review

Careful elucidation of any adverse effects

The cost-utility of the therapy

POTENTIAL CONFLICT OF INTEREST

None known.

ACKNOWLEDGEMENTS

We thank Jill Porthouse, Clare Jess and Gail Quinn of the Cochrane Gynaecological Cancer CRG for their assistance in the preparation of this review.

SOURCES OF SUPPORT

External sources of support

- No sources of support supplied

Internal sources of support

- No sources of support supplied

REFERENCES

References to studies included in this review

Clarke 2004 *{unpublished data only}*

• Clarke D, Tenorio C, Dominguez L, Toklu A, Hussey J. Treatment of radiation necrosis with hyperbaric oxygen: A randomized double-blind placebo controlled trial. *Undersea and Hyperbaric Medicine* 2004;31(Suppl):000.

Hulshof 2002 *{published data only}*

• Hulshof M, Stark N, Van der Kleij A, Sminia P, Smeding H, Gonzales D. Hyperbaric oxygen therapy for cognitive disorders after irradiation of the brain. *Strahlentherapie und Onkologie* 2002;178(4):192–8. [MedLine: 2002140155].

Marx 1985 *{published data only}*

• Marx R, Johnson R, Kline S. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. *Journal of the American Dental Association* 1985;111(1):49–54. [MedLine: 3897335].

Marx 1999a *{published data only}*

• Marx R. Bony reconstruction of the jaw. In: KindwallEP, WhelanHT editor(s). *Hyperbaric Medicine Practice*. 2nd Edition. Flagstaff, Az: Best Publishing, 1999:460–3.

Marx 1999b *{published data only}*

• Marx RE. Soft tissue flaps. In: KindwallEP, WhelanHT editor(s). *Hyperbaric Medicine Practice*. 2nd Edition. Flagstaff, Az: Best Publishing, 1999:464–8.

Pritchard 2001 *{published data only}*

Pritchard J, Anand P, Broome J, Davis C, Gothard L, Hall E, et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. *Radiotherapy and Oncology* 2001;58(3):279–86. [MedLine: 2001084162].

References to studies excluded from this review

Carl 2001

• Carl U, Feldmeier J, Schmitt G, Hartmann K. Hyperbaric oxygen therapy for late sequelae in women receiving radiation after breast-conserving surgery. *International Journal of Radiation Oncology Biology and Physics* 2001;49(4):1029–31. [MedLine: 11240244].

Coulthard 2002

Coulthard P, Esposito M, Worthington H, Jokstad A. Interventions for replacing missing teeth: hyperbaric oxygen therapy for irradiated patients who require dental implants. *Cochrane Database of Systematic Reviews* 2002, Issue 3. Art No.: CD003603. DOI: 10.1002/14651858.CD003603. Art. No.: CD003603. DOI: 10.1002/14651858.CD003603.

Denton 2002

Denton A, Forbes A, Andreyev J, Maher E. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. *Cochrane Database of Systematic Reviews* 2002 Issue 1. Art No.: CD003455. DOI: 10.1002/14651858.CD003455. Art. No.: CD003455. DOI: 10.1002/14651858.CD003455. [MedLine: 11869662].

Gal 2003

* Gal T, Yueh B, Futran N. Influence of prior hyperbaric oxygen therapy in complications following microvascular reconstruction for advanced osteoradionecrosis. *Archives of Otolaryngology - Head & Neck Surgery* 2003;129(1):72–6. [MedLine: 2003027602].

Granstrom 1999

* Granstrom G, Tjellstrom A, Branemark P-I. Osseointegrated implants in irradiated bone: a case-controlled study using adjunctive hyperbaric oxygen therapy. *Journal of Oral and Maxillofacial Surgery* 1999;57:493–9.

Maier 2000

* Maier A, Gaggli A, Klemen H, Santler G, Anegg U, Fell B, et al. Review of severe osteoradionecrosis treated by surgery alone or surgery with postoperative hyperbaric oxygenation. *British Journal of Oral and Maxillofacial Surgery* 2000;38(3):173–6. [MedLine: 10864721].

Niimi 1997

* Niimi A, Fujimoto T, Nosaka Y, Ueda M. A Japanese multicenter study of osseointegrated implants placed in irradiated tissues: a preliminary report. *International Journal of Oral and Maxillofacial Implants* 1997;12(2):259–64. [MedLine: 9109278].

Tobey 1979

* Tobey R, Kelly J. Osteoradionecrosis of the jaws. *Otolaryngology Clinics of North America* 1979;12(1):183–6. [MedLine: 375158].

References to ongoing studies

Clarke 2004b

Ongoing study Starting date of trial not provided. Contact author for more information.

Additional references

Altman 2001

Altman D, Chalmers I, Egger M, DaveySmith G. In: EggerM, Davey SmithG, AltmanD editor(s). *Systematic reviews in health care. Meta-analysis in context*. 2. London: BMJ Books, 2001:333.

Bennett 2004

Bennett M, Connor D. The database of randomised controlled trials in hyperbaric medicine. <http://www.hboevidence.com/> (accessed 06/08/04).

Clarke 2003

AldersonP, Green S, Higgins JPT, editors. *Cochrane Reviewers' Handbook 4.2.2* [updated March 2004]. *The CochraneLibrary* 2004, Issue 1.

Davis 1988

Davis JC, Buckley CJ, Barr P. Compromised soft tissue wounds: correction of wound hypoxia. In: DavisJC, HuntTK editor(s). *Problem Wounds. The Role of Oxygen*. New York: Elsevier, 1988:143–52.

Feldmeier 1995

Feldmeier JJ, Heimbach RD, Davolt DA, Court WS, Stegmann BJ, Sheffield PJ. Hyperbaric oxygen as an adjunctive treatment for delayed radiation injury of the chest wall: a retrospective review of twenty-three cases. *Undersea and Hyperbaric Medicine* 1995;22(4):383–93. [MedLine: 8574126].

Feldmeier 1998

Feldmeier JJ, Davolt DA, Court WS, OnodaJM, Alecu R. Histologic morphometry confirms a prophylactic effect for hyperbaric oxygen

in the prevention of delayed radiation enteropathy. *Undersea and*

Hyperbaric Medicine 1998;25(2):93–7. [MedLine: 9670434].

Feldmeier 2002

Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. *Undersea and Hyperbaric Medicine* 2002;29(1):4–30. [MedLine: 12507182].

Feldmeier 2003

Feldmeier J, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy?. *Undersea and Hyperbaric Medicine* 2003;30(1):1–18. [MedLine: 12841604].

Hills 1999

Hills BA. A role for oxygen-induced osmosis in hyperbaric oxygen therapy. *Medical Hypotheses* 1999;52:259–63.

Jemal 2002

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. *CA: A Cancer Journalfor Clinicians* 2002;52:23–47.

Khan 2003

Khan B, Evans AW, Easterbrook M. Refractive changes in patients undergoing hyperbaric oxygen therapy: a prospective study. *Undersea and Hyperbaric Medicine* 2003;24 (Suppl):9.

Mainous 1975

Mainous EG, Hart GB. Osteoradionecrosis of the mandible. Treatment with hyperbaric oxygen. *Archives of Otolaryngology* 1975;101(3):173–7. [MedLine: 804303].

Mandell 1974

Mandell GL. Bactericidal activity of aerobic and anaerobic polymorphonuclear neutrophils. *Infection and Immunology* 1974;9:337–41.

Marx 1988

Marx RE, Johnson RP. Problem wounds in oral and maxillo-facial surgery: the role of hyperbaric oxygen. In: DavisJC, HuntTK editor (s). *Problem Wounds: The Role of Oxygen*. New York: Elsevier, 1988: 65–123.

Marx 1990

Marx RE, Ehler WJ, Tayapongsak P. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. *American Journal of Surgery* 1990;160:519–24.

Parmar 1998

Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. *Statistics in Medicine* 1998;17:2815–34.

Pavy 1995

Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. EORTC Late Effects Working Group. Late effects toxicity scoring: The SOMA scale. *Radiotherapy and Oncology* 1995;35:11– 5.

Rubin 1968

Rubin P, Casarrett GW. *Clinical Radiation Pathology*. Vol. 1, Philadelphia, PA: WB Saunders, 1968:58–61.

Rubin 1984

Rubin P. Late effects of chemotherapy and radiation therapy: a new hypothesis. *InternationalJournal ofRadiation Oncology, Biology and Physics* 1984;10:5–34.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Journal of the American Medical Society* 1995;273(5):408–12.

Stone 2003

Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. *Lancet Oncology* 2003;4(9):529–36. [MedLine: 12965273].

Thompson 1999

Thompson IM, Middleton RG, Optenberg SA, Austenfeld MS, Smalley SR, Cooner WH, et al. Have complication rates decreased after treatment for localized prostate cancer?. *Journal of Urology* 1999; 162(1):107–12. [MedLine: 10379751].

Trott 1984

Trott KR. Chronic damage after radiation therapy: challenge to radiation biology. *International Journal of Radiation Oncology, Biology and Physics* 1984;10:907–13.

Waddell 1999

Waddell BE, Rodriguez-Bigas MA, Lee RJ, Weber TK, Petrelli NJ. Prevention of chronic radiation enteritis. *Journal of the American College of Surgeons* 1999;189(6):611–24. [MedLine: 10589598].

WHO 2004

World Health Organization sites: Cancer. <http://www.who.int/cancer/en/> 2004.

*Indicates the major publication for the study

T A B L E S

Characteristics of included studies

Study Clarke 2004

Methods	Multicentre RCT with allocation concealment and patient/outcome assessor blinding.
Participants	68 patients with problematic radiation proctitis.
Interventions	Control: Air breathing at 1ATA for 120 minutes 30 times over 6 weeks. Sham compression to trivial pressure and return. HBOT: 100% oxygen at 2.0 ATA for 30 or 40 sessions over six to eight weeks
Outcomes	Healing or significant improvement. LENT-SOMA Scores
Notes	Preliminary abstract report of one arm of 8 armed study
Allocation concealment	A – Adequate

Study Hulshof 2002

Methods Randomised trial using random number table with allocation concealment but no blinding. Randomised in matched pairs.

Characteristics of included studies (*Continued*)

Participants	7 patients with cognitive deficits present at least 1.5 years after irradiation of the brain with at least 3000 cGy.
Interventions	Control: Nil specific HBOT: 100% oxygen at 3 ATA for 115 minutes for 30 sessions over six weeks (five days out of seven each week).
Outcomes	Neuropsychiatric testing
Notes	Very low power study with many outcomes
Allocation concealment A – Adequate	
Study	Marx 1985
Methods	Multicentre randomised trial. No details of methodology for randomisation , allocation concealment or blinding.
Participants	74 patients requiring tooth extraction in a field irradiated with at least 6000 cGy more than 6 months and less than 15 years previously. Also excluded with penicillin or HBOT contraindications, active tumour present, recent chemotherapy or concurrent disease (e.g. diabetes) that might affect wound healing.
Interventions	Control: teeth extracted in standard way with 1 million units penicillin pre-extraction and 500mg four times each day for 10 days post-extraction. HBOT: 20 pre-operative treatment sessions at 2.4 ATA for 90 minutes daily five or six days each week, followed by 10 further sessions post-operatively.
Outcomes	Development of clinical osteoradionecrosis with non-healing at 6 months
Notes	
Allocation concealment B – Unclear	
Study	Marx 1999a
Methods	Described as randomised. No details concerning blinding or allocation concealment.
Participants	104 patients requiring hemimandibular jaw reconstruction in tissue beds exposed to at least 6400 cGy radiotherapy. No other specific exclusions.
Interventions	Control: Not stated HBOT: 20 pre-operative treatment sessions at 2.4 ATA for 90 minutes daily five days each week, followed by 10 further sessions post-operatively.
Outcomes	“Success” defined as achievement of continuity, restoration of alveolar bone height, restoration of osseous bulk, restoration of arch form, maintenance of bone form for 18 months and restoration of facial contours. Complication rate (infection or dehiscence).
Notes	Sketchy account within a textbook chapter written by the author.
Allocation concealment B – Unclear	
Study	Marx 1999b
Methods	Described as randomised. No details concerning blinding or allocation concealment.
Participants	160 patients requiring major soft tissue surgery or flaps into an irradiated area (>6,400 cGy). No other specific exclusions.
Interventions	Control: not stated HBOT: 20 pre-operative treatment sessions at 2.4 ATA for 90 minutes daily five days each week, followed by 10 further sessions post-operatively.
Outcomes	Wound infection, dehiscence, delayed healing
Notes	Sketchy account within a textbook chapter written by the author.

Allocation concealment B – Unclear

Study	Pritchard 2001
Methods	Randomised, allocation concealed with blinding of outcome assessors and patients.
Participants	34 patients with established radiation-related brachial plexopathy, median duration 3 years. Subjects with active tumour or contraindications to HBOT excluded.
Interventions	Control: 100 minutes at 2.4 ATA breathing 41% oxygen to simulate 100% oxygen at 1ATA, daily 5 days per week to a total of 30 sessions. HBOT: 100% oxygen breathing on the same schedule.
Outcomes	Sensory thresholds, quality of life scores, McGill pain Score, lymphoedema resolution
Notes	Many other outcomes reported

Allocation concealment A – Adequate

ATA: Atmospheres absolute

Brachial plexopathy: Poor functioning of the nerves going through the armpit to supply the arm and resulting in loss of sensation, muscle power and function in the arm.

cGy: Centi-Grey

H B O T : H y p e r b a r i c o x y g e n t h e r a p y

Characteristics of excluded studies

Study	Reason for exclusion
Carl 2001	Case series only, no randomised comparator
Coulthard 2002	Systematic review - no new data
Denton 2002	Systematic review - no new data
Gal 2003	Retrospective cohort study
Granstrom 1999	Case control study - not randomly allocated
Maier 2000	Retrospective cohort study
Niimi 1997	Cohort study
Tobey 1979	RCT but no quantitative data given. Both arms received some HBOT (1.2 versus 2.0 ATA)

ADDITIONAL TABLES

Table 01. The LENT-SOMA Scales - Conceptual summary

(S)ubjective	(O)bjective	(M)edical management	(A)nalytic
The injury from the patient point of view. May involve interview, diary or questionnaire depending on the system to be used.	Morbidity assessed objectively by clinician during physical examination.	The active steps that have been taken in order to ameliorate the symptoms.	Diagnostic and imaging tools used to further objectively define the level of injury.

Table 02. Search Strategies

EMBASE

1. exp radiation injury/
2. (head or neck or cerebr\$ or cervi\$ or brain\$ or pelvi\$ or mandib\$ or chest or uter\$ or bladder or bowel or rect\$).mp.
3. (radiation\$ or radiotherap\$ or late\$ or damag\$ or wound\$ or destruction\$ or oedema\$ or edema\$ or fracture\$).mp
4. 2 and 3
5. 1 or 4
6. exp radiotherapy/
7. 5 or 6
8. exp hyperbaric oxygen/
9. (high adj5 (pressur\$ or oxygen\$)).mp.
10. hyperbaric\$.mp.
11. 8 or 9 or 10
12. oxygen\$.mp.
13. 11 and 12
14. (HBO or HBOT).mp.
15. multiplace chamber\$.mp.
16. monoplace chamber\$.mp.
17. 13 or 14 or 15 or 16
18. 7 and 17
19. 18

MEDLINE (OVID)

1. exp radiation injuries
2. exp radiotherapy
3. head or neck or cervi* or pelvi* or mandib* or chest or uter* or bladder or bowel or rect* or leg
4. radiation* or radiation inj* or late or damage* or wound* or destruction* or oedema* edema* or fracture*
5. 3 and 4
6. 1 or 2 or 5
7. exp hyperbaric oxygenation
8. (high*) adj3 (pressure or tension*)
9. hyperbaric*
10. oxygen*
11. 6 or 7 or 8
12. 9 and 10
13. HBO or HBOT
14. multiplace chamber*
15. monoplace chamber*
16. 11 or 12 or 13 or 14 or 15
17. 16 and 17

ANALYSES

Comparison 02. Complete resolution of problem

Outcome title	No. of studies	No. of participants	Statistical method	No. of	Effect size
01 Complete resolution of clinical problem at three months			Relative Risk (Random) 95% CI		Subtotals only
02 Sensitivity analysis for missing data in proctitis (best case)	1	68	Relative Risk (Fixed) 95% CI	3.33	[1.53, 7.26]
03 Sensitivity analysis for missing data in proctitis (worst case)	1	68	Relative Risk (Random) 95% CI	1.23	[0.71, 2.15]

Comparison 03. Improvement in mean LENT-SOMA score

Outcome title	No. of studies	No. of participants	Statistical method	No. of	Effect size
01 Mean LENT-SOMA score at three months	1	57	Weighted Mean Difference (Fixed) 95% CI	3.97	[1.69, 6.25]

Comparison 04. Resolution of pain

Outcome title	No. of studies	No. of patients	Statistical method	Results
01 Pain score change at end of treatment	1	34	Weighted Mean Difference (Fixed) 95% CI	Not estimable
02 Pain score change at one year	1	34	Weighted Mean Difference (Fixed) 95% CI	Not estimable

Comparison 05. Resolution of swelling

Outcome title	No. of studies	No. of patients	Statistical method	Results
01 Improvement of lymphoedema	1	34	Relative Risk (Fixed) 95% CI	5.00 [0.26, 97.00]

Comparison 06. Improvements in quality of life or function

Outcome title	No. of studies	No. of patients	Statistical method	Results
01 SF-36 mean score at twelve months (general health)	1	34	Weighted Mean Difference (Fixed) 95% CI	-2.30 [-18.95, 14.35]
02 SF-36 mean score for physical function at 12 months	1	34	Weighted Mean Difference (Fixed) 95% CI	-4.00 [-19.40, 11.40]

Comparison 07. Osteoradionecrosis

Outcome title	No. of studies	No. of patients	Statistical method	Results
01 Complete mucosal cover	2	178	Relative Risk (Fixed) 95% CI	1.38 [1.19, 1.61]
02 Establishment of bony continuity	1	104	Relative Risk (Fixed) 95% CI	1.41 [1.14, 1.75]
03 Successful healing of tooth sockets after tooth extraction	1	74	Relative Risk (Fixed) 95% CI	1.35 [1.08, 1.68]

Comparison 11. Head and Neck

Outcome title	No. of studies	No. of patients	Statistical method	Results
01 Wound dehiscence	2	264	Relative Risk (Random) 95% CI	4.23 [1.06, 16.83]

Comparison 12. Neurological tissue

Outcome title	No. of studies	No. of patients	Statistical method	Results
03 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline)	1	34	Weighted Mean Difference (Fixed) 95% CI	1.12 [-1.90, 4.14]
04 Warm sensory threshold at one year	1	34	Weighted Mean Difference (Fixed) 95% CI	-0.87 [-3.97, 2.23]
06 Net number of significantly improved neuropsychological tests at three months (25 tests total)	1	7	Weighted Mean Difference (Fixed) 95% CI	2.00 [-1.60, 5.60]

07 Net number of significantly improved neuropsychiatric tests at six months	1	7	Weighted Mean Difference (Fixed) 95% CI	1.00 [-3.55, 5.55]
--	---	---	---	--------------------

INDEX T E R M S

Medical Subject Headings (MeSH)

* Hyperbaric Oxygenation; Neoplasms [radiotherapy]; Osteoradionecrosis [prevention & control]; Radiation Injuries [prevention & control; therapy]; Randomized Controlled Trials

MeSH check words

Humans

COVER S H E E T

Title	Hyperbaric oxygen therapy for late radiation tissue injury
Authors	Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C
Contribution of author(s)	Micheal Bennett: Principal author, conception, search strategy and execution, data extraction and critical appraisal, hyperbaric medicine content expert, statistical analysis. John Feldmeier: Co-author, data extraction and critical appraisal, radiation oncology and hyperbaric medicine content expert. Neil Hampson: Co-author, editorial advice, data extraction and critical appraisal, hyperbaric medicine content expert. Chris Milross: Co-author background, radiation oncology content expert. Robert Smee: Editorial advice, radiation oncology content expert.
Issue protocol first published	2004/2
Review first published	2005/3
Date of most recent amendment	24 May 2005
Date of most recent SUBSTANTIVE amendment	23 May 2005
What's New	Information not supplied by author
Date new studies sought but none found	Information not supplied by author
Date new studies found but not yet included/excluded	Information not supplied by author
Date new studies found and included/excluded	Information not supplied by author
Date authors' conclusions section amended	Information not supplied by author
Contact address	A/Prof Michael Bennett Medical Director Diving and Hyperbaric Medicine Prince of Wales Hospital Barker Street Randwick NSW

2031
 AUSTRALIA
[E-mail: m.bennett@unsw.edu.au](mailto:m.bennett@unsw.edu.au)
 Tel: +61 2 9382 3880
 Fax: +61 2 9382 3882


DOI 10.1002/14651858.CD005005.pub2
 Cochrane Library number CD005005
 Editorial group Cochrane Gynaecological Cancer Group
 Editorial group code HM-GYNAECA

GRAPHS AND OTHER TABLES

Analysis 02.01. Comparison 02 Complete resolution of problem, Outcome 01 Complete resolution of clinical problem at three months

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 02 Complete resolution of problem


Outcome: 01 Complete resolution of clinical problem at three months



Analysis 02.02. Comparison 02 Complete resolution of problem, Outcome 02 Sensitivity analysis for missing data in proctitis (best case)

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 02 Complete resolution of problem


Outcome: 02 Sensitivity analysis for missing data in proctitis (best case)



Analysis 02.03. Comparison 02 Complete resolution of problem, Outcome 03 Sensitivity analysis for missing data in proctitis (worst case)


Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 02 Complete resolution of problem

Outcome: 03 Sensitivity analysis for missing data in proctitis (worst case)



Analysis 03.01. Comparison 03 Improvement in mean LENT-SOMA score, Outcome 01 Mean LENT-SOMA score at three months


Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 03 Improvement in mean LENT-SOMA score Outcome: 01 Mean LENT-SOMA score at three months



Analysis 04.01. Comparison 04 Resolution of pain, Outcome 01 Pain score change at end of treatment

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 04 Resolution of pain


Outcome: 01 Pain score change at end of treatment



Analysis 04.02. Comparison 04 Resolution of pain, Outcome 02 Pain score change at one year

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 04 Resolution of pain


Outcome: 02 Pain score change at one year



Analysis 05.01. Comparison 05 Resolution of swelling, Outcome 01 Improvement of lymphoedema

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 05 Resolution of swelling

Outcome: 01 Improvement of lymphoedema




Analysis 06.01. Comparison 06 Improvements in quality of life or function, Outcome 01 SF-36 mean score at twelve months (general health)

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 06 Improvements in quality of life or function

Outcome: 01 SF-36 mean score at twelve months (general health)




Analysis 06.02. Comparison 06 Improvements in quality of life or function, Outcome 02 SF-36 mean score for physical function at 12 months

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 06 Improvements in quality of life or function

Outcome: 02 SF-36 mean score for physical function at 12 months




Analysis 07.01. Comparison 07 Osteoradionecrosis, Outcome 01 Complete mucosal cover

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 07 Osteoradionecrosis


Outcome: 01 Complete mucosal cover



Analysis 07.02. Comparison 07 Osteoradionecrosis, Outcome 02 Establishment of bony continuity

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 07 Osteoradionecrosis


Outcome: 02 Establishment of bony continuity



Analysis 07.03. Comparison 07 Osteoradionecrosis, Outcome 03 Successful healing of tooth sockets after tooth extraction

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 07 Osteoradionecrosis


Outcome: 03 Successful healing of tooth sockets after tooth extraction



Analysis 11.01. Comparison 11 Head and Neck, Outcome 01 Wound dehiscence

Review: Hyperbaric oxygen therapy for late radiation tissue injury Comparison: 11 Head and Neck

Outcome: 01 Wound dehiscence




Analysis 12.03. Comparison 12 Neurological tissue, Outcome 03 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline)

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 12 Neurological tissue

Outcome: 03 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline)




Analysis 12.04. Comparison 12 Neurological tissue, Outcome 04 Warm sensory threshold at one year

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 12 Neurological tissue

Outcome: 04 Warm sensory threshold at one year




Analysis 12.06. Comparison 12 Neurological tissue, Outcome 06 Net number of significantly improved neuropsychological tests at three months (25 tests total)

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 12 Neurological tissue

Outcome: 06 Net number of significantly improved neuropsychological tests at three months (25 tests total)



Analysis 12.07. Comparison 12 Neurological tissue, Outcome 07 Net number of significantly improved neuropsychiatric tests at six months

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 12 Neurological tissue

Outcome: 07 Net number of significantly improved neuropsychiatric tests at six months

Study	HBOT		Control		Weighted Mean Difference (Fixed)	Weight (%)	Weighted Mean Difference (Fixed)
	N	Mean(SD)	N	Mean(SD)	95% CI		95% CI
Hulshof 2002	4	3.00 (4.50)	3	2.00 (1.00)		100.0	1.00 [-3.55, 5.55]
Total (95% CI)	4		3			100.0	1.00 [-3.55, 5.55]

Test for heterogeneity: not applicable
 Test for overall effect z=0.43 p=0.7

-10.0 -5.0 0 5.0 10.0
 Favours control Favours HBOT